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Chronic lifestyle stress translates to chronic physiological and psychological conditions. Continual stress-response 
activation plays a key role in the development of inflammatory diseases, such as diabetes, Alzheimer’s disease, anxiety 
and depression. It is known that inflammatory cytokines produced in the periphery can cross the blood-brain barrier, 
resulting in release of neurotoxins that can lead to demise of central nervous system integrity. Pro-inflammatory 
cytokines are also responsible for undesired modulation of serotonin signalling and receptor expression. Since two of 
the major systems implicated in the aetiology of neurodegeneration and psychological illness are central inflammation 
and maladaptations in serotonergic signalling, it is important to investigate potential therapeutic targets in this 
context.  
A high-mesembrine Sceletium tortuosum extract (Trimesemine™) was shown to possess cytoprotective and mild anti-
inflammatory properties in human monocytes, and inhibitory effects on adrenal glucocorticoid synthesis. Additionally, 
it was recently confirmed that claimed selective serotonin reuptake inhibition (SSRI) properties of Sceletium tortuosum 
are, in fact, secondary to its monoamine-releasing agent (MRA) capacity. A high-Δ7-mesembrenone Sceletium extract 
has also shown promising anti-oxidant capacity and anti-cancer effects. In this thesis, two models were employed to 
further investigate the therapeutic potential of Sceletium tortuosum in maladaptations to chronic stress. 
Firstly, the central immunomodulatory effects of two Sceletium tortuosum extracts, high-mesembrine extract, 
Trimesemine™, and high-Δ7-mesembrenone extract, Delta-7, were investigated. Human astrocytes were pre-treated 
with each extract for 30 minutes, before exposure to Escherichia coli lipopolysaccharide for 23.5 hours (in the presence 
of treatment). Cytotoxicity, mitotoxicity and cytokine responses (basally and in response to inflammatory stimulus) 
were assessed. Total polyphenol content, antioxidant capacity and selected neural enzyme inhibition capacity were 
also assessed for both extracts. Trimesemine™ exerted cytoprotective (p<0.0001) and anti-inflammatory effects 
(p<0.05). In contrast, Delta-7 exhibited potent antioxidant effects (p<0.05), although with relatively higher risk of 
adverse effects with overdose. 
The second model employed was a platelet model of the central serotonergic system, to investigate the effects of 
high-mesembrine Sceletium on serotonin system parameters in anxious and non-anxious individuals. Modulators of 
the serotonergic system – an SSRI (citalopram) and a mild MRA (Trimesemine™) – were used to investigate the platelet 
model in anxiety. Isolated platelets from anxious and non-anxious subjects were exposed to a known activator (calcium 
ionophore A23187) and each modulator for 15 minutes. Cytokine secretion and changes in platelet serotonergic 
system activity were assessed. Serotonin transporter expression was down-regulated in state anxiety in response to 
citalopram, validating the platelet model in this context. Basal platelet serotonin levels in individuals exhibiting 
state/trait anxiety were lower than no-anxiety controls (p<0.05), while platelet activation state was increased (p<0.05). 
Trimesemine™ was again confirmed to have anti-inflammatory effect by its modulation of pro- and anti-inflammatory 
cytokine secretion.  
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We conclude that both Sceletium tortuosum extracts may be employed as either a preventative supplement or 
complimentary treatment in the context of chronic immune-mediated disease. This study has also highlighted key 
differences between anxious and non-anxious individuals, and between anxiety type, in terms of serotonergic system 
parameters and inflammatory responses, suggesting diagnostic potential for the platelet model. 
 
  




Chroniese leefstylstres lei to chroniese fisiologiese en sielkundige toestande. Voortdurende aktivering van die stress 
respons speel ‘n groot rol in die ontwikkeling van inflammatoriese siektes/toestande, soos diabetes, Alzheimer se 
siekte, angstigheid en depressie.  Dit is bekend dat sitokiene wat in die periferie vervaardig word, die bloed-breinskans 
kan oorsteek en kan lei tot die afskeiding van neurotoksiene wat weer die integriteit van die sentrale senuweestelsel 
kan aftakel.  Pro-inflammatoriese sitokiene is ook vir ongewenste veranderings in reseptor uitdrukking en serotonien 
seinoordrag verantwoordelik.  Aangesien sentrale inflammasie en wanaangepaste serotonien seinoordrag sentraal 
staan tot die ontwikkelling van neurodegenerasie en psigologiese siektes, is dit bepaald belangrik om moontlike 
terapeutiese teikens in hierdie konteks te ondersoek.   
‘n Sceletium tortuosum ekstrak met hoë mesembrien inhoud (Trimesemine™) het bewese sitobeskermende en ligte 
anti-inflammatoriese eienskappe, soos geïllustreer in monosiete, asook beperkende effekte op bynier glukokortikoïed 
sintese. Onlangse navorsing het ook bewys dat die selektiewe serotonien heropname inhibisie (SSRI) effek wat 
algemeen aanvaar word vir die ekstrak, eintlik sekondêr is tot ‘n mono-amien vrystellings (MRA) funksie. In voorlopige 
studies het ‘n Sceletium tortuosum ekstrak met hoë Δ7-mesembrenoon inhoud ook belowende anti-oksidant en 
teenkankereffekte getoon. In hierdie tesis word twee modelle gebruik om die terapeutiese potensiaal van Sceletium 
tortuosum in die konteks van wanaanpassings as gevolg van chroniese stres, verder toe te lig.  
Eerstens is die sentrale immuun-modulerende effekte van twee Sceletium tortuosum ekstrakte – een met hoë 
mesembrien inhoud, Trimesemine™, en een met hoë Δ7-mesembrenoon inhoud, Delta-7, ondersoek. Menslike 
astrosiete is vir 30 minute voorafbehandel met elke ekstrak, waarna dit vir 23.5 uur aan Escherichia coli 
lipopolisakkaried blootgestel is (in die teenwoordigheid van ekstrak). Sitotoksisiteit, mitotoksisiteit en sitokienreaksies 
(beide basal en in reaksie op die inflammatoriese stimulus) is bepaal. Totale polifenoolinhoud, anti-oksidant kapasiteit 
en inhibisie van relevante neurale ensieme is ook vir beide ekstrakte bepaal.  Trimesemine™ het sitobeskermende 
(p<0.0001) en anti-inflammatoriese (p<0.05) effekte getoon. In kontras daarmee, het Delta-7 sterk anti-oksidant 
effekte getoon (p<0.05), alhoewel dit met ‘n relatiewe hoër risiko vir ongewenste effekte van oordosering verbind kan 
word. 
Die tweede model was ‘n plaatjie-model van die sentrale serotonergiese sisteem, waarmee die effek van hoë-
mesembrien Sceletium op parameters van die serotonien sisteem in beide angstige en nie-angstige individue bepaal 
is. Moduleerders van die serotonergiese sisteem – ‘n SSRI (citalopram) en ‘n ligte MRA (Trimesemine™) – is aangewend 
om die plaatjiemodel in die konteks van angstigheid te toets. Plaatjies geïsoleer uit angstige en nie-angstige skenkers 
is vir 15 minute saam met ‘n bekende aktiveerder (calcium ionophore A23187) aan elke moduleerder blootgestel. 
Sitokien afskeiding en veranderinge in plaatjie parameters wat die serotonien sisteemaktiwiteit aandui, is bepaal. 
Serotonien vervoerreseptor (SERT) uitdrukking is afgereguleer na citalopram behandeling, in toestand-angstigheid, 
wat die plaatjie-model bekragtig. Basale plaatjie serotonienvlakke was laer in individue met beide toestand- en 
eienskap-angstigheid, in vergelyking met nie-angstige kontroles (p<0.05), terwyl plaatjie aktiveringstatus verhoog was 
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(p<0.05). Anti-inflammatoriese effek van Trimesemine™ is weer bevestig met die modulering van pro- en anti-
inflammatoriese sitokiene.  
Ten slotte bevind ons dat beide Sceletium tortuosum ekstrakte as voorkomende of komplimentêre behandeling in die 
konteks van chroniese siekte gebruik kan word. Hierdie studie lig ook belangrike verskille tussen angstige en nie-
angstige individue, asoos tipes angstigheid, uit, in terme van parameters van die serotonien sisteem en 
inflammatoriese reaksies, wat diagnostiese potensiaal van die plaatjie-model mag aandui.  
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Chapter 1 – Introduction 
Despite stress having largely negative associations, it is an ever-present aspect of daily life, acting as a driving 
force for some, but as a burden for most individuals. A cohesive description of stress indicates that it consists 
of a stressor (in any form) that prompts a reaction in the brain and activates stress-response systems within 
the body (McTeague and Lang, 2012; Morag et al., 1999; Padgett and Glaser, 2003). 
Continual, unrelenting lifestyle stress resulting from everyday stressors that are poorly managed, or from 
traumatic events, has been found to translate to chronic psychological conditions (Ross et al., 2017). It is 
therefore understandable that the prevalence of common mental health disorders is on the rise. From 1990 
to 2013 alone, the number of reported cases of anxiety and/or depression increased by ±50%. Almost 10% 
of the global population are afflicted, with mental health disorders accounting for 30% of the world’s non-
fatal disease burden (World Health Organisation, 2016). 
Besides the obvious morbidity that accompanies chronic anxiety and depression, continual stress-response 
activation plays a key role in the development of inflammatory lifestyle diseases such as type 2 diabetes 
(T2D), cardiovascular diseases, autoimmune diseases (O’Donovan et al., 2014), allergies, Alzheimer’s disease 
and pain (Himmerich et al., 2008; Kiecolt-Glaser et al., 2015; Knol et al., 2006; Postal and Appenzeller, 2015). 
Likewise, the presence of these conditions is also characterised by an elevated risk for development of mental 
health disorders (Dantzer et al., 2008; Walker et al., 2014), indicating a distinct, self-perpetuating relationship 
between central and peripheral maladaptations to physiological and psychological stress. 
It is also commonly known that an extended process is often required to arrive at suitable dose and type of 
anti-depressant or anxiolytic drugs for any individual because of suboptimal diagnostic practise, since 
observing pathological changes within the central nervous system (CNS) remains significantly more 
challenging than for peripheral organs. This is mainly due to anatomic restrictions, as well as the relative risks 
involved in acquiring brain samples for further investigation. 
Current therapeutic options for mental health disorders mainly focus on modulation of the serotonergic 
system, either through increasing serotonin availability in synapses within the CNS or prolonging its signalling 
time by preventing reuptake into the presynaptic neuron. Modulators of this system have also been found 
to possess anti-inflammatory properties (Abdel-Salam et al., 2004; Sawynok et al., 2001), substantiating the 
distinct link between the serotonergic- and the inflammatory immune systems. However, current drugs 
employed for the treatment of anxiety and/or depression are known to elicit adverse effects such as 
drowsiness, nausea, headaches, and reduced libido. 
Recently, interest in the herbal supplement, Sceletium tortuosum, has been on the rise, as it may be beneficial 
in reducing the symptoms of anxiety and depression (Shikanga et al., 2012; Smith and Weyrich, 2011), as well 
as limit the inflammatory response and glucocorticoid (GC) synthesis (Swart and Smith, 2016). These findings 
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highlight the key role that Sceletium tortuosum extract supplementation – alone or in conjunction with other 
commercial anxiolytic/antidepressant drugs – may play in the treatment of non-communicable inflammatory 
disorders, However, research data from physiologically-relevant models is still scant. 
The following chapter will introduce the complexity of the chronic stress-chronic inflammation-chronic 
disease relationship, with a specific focus on its contribution to the pathophysiology of inflammatory mental 
health disorders, with specific focus on neurodegeneration and anxiety. A potentially novel model in the 
context of the diagnosis and therapeutic monitoring of anxiety will then be explored, drawing parallels to 
central neurons most affected in this condition. Lastly, current pharmaceuticals employed in the treatment 
of anxiety/depression disorders will be discussed, followed by a reference to Sceletium tortuosum as a 
potential treatment, given its similar pharmacological actions to popular commercial drugs in this setting, 
and promising immunomodulatory properties. 
This thesis is divided into two major bodies of work, based on manuscripts that have been submitted for 
publication in two different journals (Journal of Physiology and Biochemistry and Journal of Affective 
Disorders) and are currently under review for publication. Thus, general background pertaining to both 
bodies of work will be covered in Chapter 2, but more detailed literature most specific to the two different 
experiments will introduce each respective chapter. 
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Chapter 2 – Literature Review 
The sheer size of the recent body of literature on chronic inflammatory illnesses testifies to the increasing 
incidence of these conditions and the relative burden its places on not only personal health, but also the 
health care system and society in general. From my review of the literature, it became evident that most 
non-communicable inflammatory diseases have interlinked aetiologies. Inflammation and poor lifestyle 
habits are central to the progression from adaptation to maladaptation to various initial triggers. A 
complexity in this context is that various factors interlink, forming a tangle of self-propagating cycles 
(presented in Figure 2.1), so that once initiated, it is very difficult to discern specific primary causes to target 
therapeutically. 
 
Figure 2.1: A summary of the complex relationship between chronic stress, inflammation and the development 
of chronic central and peripheral disease 
For this thesis, I have narrowed the scope to focus on physiological systems associated with the modern 
stressful lifestyle. In particular, I will focus on the serotonergic and inflammatory immune systems in the 
context of anxiety/depression. However, cross-links to other chronic diseases cannot be disregarded – for 
example, obesity has been described as a risk factor for mental health disorders (Anstey et al., 2011; Silić et 
al., 2012). Thus, I will attempt to interpret my experimental data relevant to not only anxiety/depression, but 
also other conditions as applicable.  
In the next few pages, I will provide a brief description of the physiology of anxiety and depression. This will 
include most common causes of these conditions, as well as the major role players involved in stress-immune 
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cross-talk.  I then move on to discuss how these systems may be modulated for therapeutic effect, or as 
preventative measure. Given the obvious difficulty of investigating potential modulation of the serotonergic 
system, I argue the potential of using peripheral blood platelets as model with which to simulate the 
serotonergic system. Lastly, I present available literature on a natural product which hold potential as natural 
medicine in this context.   
 The Physiology of Anxiety and Depression 
Anxiety disorders are consistently reported to be the most prevalent of mental health disorders, with an 
estimated 12-month prevalence of 11% and a lifetime prevalence of 16% (Kessler et al., 2011). Additionally, 
depression affects approximately 4% of the total world population (World Health Organisation, 2017). The 
significant co-morbidity of anxiety and depression accounts for up to 70% of patients with one disorder 
experiencing the other during their lifetime (Gorman, 1996). 
In my opinion, the maladaptations of the body’s control systems (endocrine, immune and neural) are present 
– but not reliably monitored or detected – long before clinical manifestation of the physical symptoms of 
chronic disease. In support of this, many of these early-onset maladaptations are important predictors of 
subsequent onset of a number of physical morbidities (Knol et al., 2006; Ormel et al., 2007). 
Following an extensive review of the literature, it was concluded that although anxiety and depression are 
two distinctly different conditions, once clinical pathology has set in, the two cannot be reliably separated, 
as one is rarely observed without the other. This of course adds complexity to integrative interpretation of 
the literature on this topic. Thus, although anxiety is the context for this thesis, I will present literature 
covering both anxiety and depression, in terms of their maladaptations and their contributions to 
inflammation and chronic disease development. 
2.1.1 Pathophysiology in anxiety  
The concept of fear can be defined as a general response to unknown threats or to internal conflict. Anxiety 
is a more exacerbated form of fear, combining subjective emotional distress with physiological stress-
response activation and fear behaviour (McTeague and Lang, 2012; Steimer, 2002). Since the main role of 
fear is to trigger adaptive responses to maintain homeostasis, it is understandable that anxiety stems from 
exaggerated fear-mediating mechanisms that have been developed to protect us from distant threats, rather 
than immediate ones. Despite anxiety being a natural reaction, it can develop into a pathological inability to 
cope with stressful events, characterised by exaggerated emotional responses to stimuli that are perceived 
as innocuous or only mildly threatening by others (McTeague and Lang, 2012). 
Three major vulnerability concepts for anxiety development in humans have been defined: (i) generalised 
biological vulnerability of genetic origin, (ii) generalised psychological vulnerability, due to early life 
experiences, and (iii) specific psychological vulnerability, resulting from particular traumatic life events (Behar 
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et al., 2009). While the first two concepts are mostly implicated in the development of generalized anxiety 
disorders, the latter is significant in the development of specific anxiety disorders such as obsessive-
compulsive disorder, social phobia and panic disorder (Steimer, 2002). 
Normal arousal in the fear response results from increased excitability of serotonergic, GABA-ergic and 
noradrenergic neurons (Roth, 2005), in preparation for physical reactions to a perceived threat. An increase 
in sympathetic signalling via the sympathetic-adrenal-medullary (SAM) axis results in preparation for the 
fight-or-flight response, and hormones released through the hypothalamic-pituitary-adrenal (HPA) axis 
mediate energy store release (more detail on this in the following section). 
Sustained arousal through chronic anxiety can deplete neurotransmitters, affect receptor expression and 
cause chronic stress-response signalling, resulting in the development of emotional and somatic depressive 
symptoms (Charney and Drevets, 2002; Gorman, 1996; Steimer, 2002). 
2.1.2 Pathophysiology in depression 
The core, overlapping symptoms of anxiety and clinical depression include irritability and agitation, 
concentration difficulties, and disrupted sleeping and eating patterns (Gorman, 1996; Nestler et al., 2002). 
Brain areas mostly implicated in these mental disorders are those involved in emotion processing, emotional 
memory formation and retrieval, including the prefrontal cortex, subgenual cingulate cortex, subcortical 
hippocampus and the amygdala (Krishnan and Nestler, 2008; Ressler and Mayberg, 2007). 
Biological maladaptations common to both anxiety and depression include altered serotonin (5-
hydroxytryptamine, 5-HT) transmission and HPA axis dysfunction (Zangrossi and Graeff, 2014). 5-HT is a 
monoamine that regulates a range of functions in both the central nervous system (CNS) and in the peripheral 
compartment (Berger et al., 2009; Jacobs and Azmitia, 1992; Ressler and Mayberg, 2007). 
In contrast to 5-HT hypersecretion in anxiety, depression results from ineffective post-synaptic 5-HT 
transmission. 5-HT1A receptors, the main inhibitory 5-HT receptor subtype responsible for limiting the effects 
of serotonergic signalling within the CNS and periphery, increase in response to elevations in circulating 5-
HT. Ultimately, this results in a decrease in 5-HT transmission (Fajardo et al., 2003) - and depressive 
symptomology - since 5-HT regulates a broad range of behaviours and processes, including mood, appetite, 
memory, aggression and sleep. 
Since the development of anxiety and depression is largely attributed to maladaptation of the major stress-
response systems, which are subsequently further stimulated by the bi-products of these mental health 
disorders, one can understand the unavoidable overlap in literature on anxiety and depression research. 
Since chronic stress is a major contributor to the overstimulation of physiological stress-response 
mechanisms, it is important to cover its role in this context in more detail. 
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2.1.3 How does chronic stress cause anxiety/depression? 
This section provides basic information on the normal functioning and related role-players of three chosen 
major mechanisms that link the stress and immune systems, before discussing these maladaptive processes 
in more detail in the context of anxiety/depression. 
2.1.3.1 Cytokines 
All inflammatory cytokines can be secreted under various conditions, and these molecules can stimulate a 
range of effector functions of both innate and adaptive immunity (Medzhitov and Janeway, 1997). The net 
effect of any human cytokine is dependent on the timing of cytokine release, the environment in which it 
exerts its effect, the presence of antagonist or synergistic elements, and the tissue responsiveness (Barak et 
al., 2002; Blanco et al., 2008; Dinarello, 1997). 
Inflammatory cytokines such as tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6) 
and interleukin-8 (IL-8) are known as multi-potential mediators of the immune system, as they have a wide 
range of biological activities. Depending on their local concentration, they can have favourable or 
unfavourable effects on the host inflammatory response (Barak et al., 2002). 
Dysregulation of the functional action of the immune system in chronically stressed patients is a 
phenomenon that has been confirmed many times (Anisman and Merali, 2002; Iwata et al., 2013; Kiecolt-
Glaser et al., 2015; Miller et al., 2009; Schiepers et al., 2005). In 1999, Maes proposed the “IRS model of major 
depression”, which explains that mental health disorders may be linked to chronic stimulation of the 
inflammatory response system. Per this model, anxiety and depression are classified as psycho-neuro-
immunological disorders, in which the continued low-level release of pro-inflammatory cytokines by 
activated immune cells is responsible for the range of maladaptive behaviours and neuroendocrine changes 
associated with this condition. This assumption has been consistently expressed as a range of hypotheses, all 
with common backbone. A summary of these can be seen in Table 2.1.  
Table 2.1: A summary of the major inflammation-mental health disorder hypotheses 
Hypothesis Comments References 
The monocyte-T lymphocyte 
hypothesis 
Activated macrophages 
contribute to the 
pathophysiology of depression by 
direct IL-1β stimulation on the 
HPA-axis (see HPA-axis 
hyperactivity hypothesis). 
(Leonard, 2001; Maes, 1995; 
Maes et al., 1998) 
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IRS model of depression 
Major depression results from 
products of a dysregulated 
inflammatory response system. 




HPA axis hyperactivity results in 
decreased GR expression; 
therefore, inflammatory 
cytokines are persistently 
secreted, interfering with 5-HT 
turnover and ultimately 
development of depressive 
symptoms. 
(Dantzer et al., 2008; Flandreau 
et al., 2012) 
The cytokines hypothesis of 
depression 
Chronic peripheral immune 
challenge can induce 
neuroinflammation, resulting in 
changes in neurotransmitter 
metabolism which may lead to 5-
HT deficiency. 
 
Depression may be a sickness 
behaviour result from chronic 
immune cell activation. 




Mood disorders are attributed to 
an abnormal proneness to 
systemic inflammation 
(specifically those suffering from 
inflammatory lifestyle diseases, 
and aged populations) 
(Dantzer et al., 2008)  
The monoamine hypothesis of 
depression 
Chronic circulating pro-
inflammatory cytokines reduce 
tryptophan availability in the CNS 
and interfere with 5-Ht 
production 
(Capuron et al., 2003; Leonard, 
2014; Maes et al., 2011) 
 
Significant similarities exist between cytokine-induced sickness behaviour and anxiety/depression. Both 
conditions are characterised by physical and social withdrawal, pain, fatigue and low mood (Dantzer, 2004; 
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Dantzer et al., 2008).  Major pro-inflammatory maladaptations exist in patients with mental health disorders 
in comparison to healthy controls (Miller et al., 2009; Valkanova et al., 2013). This supports the idea of an 
interconnectedness of anxiety, depression and inflammation. A summary of the major cytokines assessed in 
anxiety/depression research is provided in Table 2.2. 
Table 2.2: Common cytokines/chemokines used as biomarkers in chronic stress and anxiety/depression 
research 
Cytokine/chemokine Comments References 
C-reactive protein Elevated levels in blood of depressed patients. (Leonard, 2014) 
IL-10 
Serum levels are reduced in patients with depression. 
Subjects with stress-induced anxiety showed 
significantly lower serum IL-10. 
(Berk et al., 2013; 
Leonard, 2014, 2001; 
Maes et al., 1998) 
IL-1β 
Systemic administration of lipopolysaccharide (LPS) in 
rats induces IL-1β secretion in the CNS, resulting in 
sickness behaviour. 
Plasma IL-1β levels were significantly elevated 
(p<0.05) in depressed patients. 
(Anisman and Merali, 
2002; Dahl et al., 2014; 
Dantzer et al., 2008; 
Lopresti et al., 2014) 
 
IL-6 
Peripheral marker of chronic stress-related 
inflammation. Associated with an increased risk of 
development of depressive symptoms. 
Dysregulated sleep patterns in anxiety/depression 
associated with increased IL-6 levels. 
SSRI treatment causes a decrease in IL-6 and TNF-α 
levels. 
(Frommberger et al., 
1997; Lopresti et al., 
2014; Miller et al., 2009; 
Valkanova et al., 2013) 
IL-8 
Plasma IL-8 levels were significantly elevated (p<0.05) 
in depressed patients. 
(Dahl et al., 2014) 
MCP-1 
Elevated levels in the cerebral-spinal fluid in patients 
with mood and anxiety disorders. 
(Mackay, 2015) 
Platelet factor-4 
Increased platelet secretion of platelet factor-4 (PF-4) 





Under normal conditions: important for enhancing 
neurogenesis and providing trophic support. 
Elevated serum concentrations in depressed patients 
compared to controls. 
(Dahl et al., 2014; 
Dowlati et al., 2010; 
Himmerich et al., 2008; 
Miller et al., 2009; Postal 
and Appenzeller, 2015) 
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Elevated levels in the CNS contribute to 
neurodegeneration, oxidative stress and apoptosis of 
astrocytes. 
 
The benefit of having an established panel of cytokine biomarkers for mental health disorder characterisation 
is that their presence or absence can be used to indicate probability of onset or estimate current disease 
status. In addition, biomarkers can be used to classify disorder severity based on the maladaptations present. 
Most importantly, they may be useful indicators of therapeutic efficacy and provide insight into a patient’s 
personal responses to treatment options. 
Excessive cytokine production in any setting can cause damage (Lu et al., 2010; Streit et al., 2004). Therefore, 
limitation of inflammatory cytokine production – in circulation, but also specifically locally at tissue level – 
should be beneficial for prevention of chronic systemic inflammation, and consequent development of 
inflammation-related illness (Lu et al., 2010; Rothwell and Hopkins, 1995; Streit et al., 2004). 
In summary, the immune system is regulated, to a significant extent, by both the central and peripheral 
nervous systems, with bidirectional communication occurring between these two systems, in conjunction 
with the endocrine system (Basu and Dasgupta, 2000; Padgett and Glaser, 2003). Therefore, it is important 
to next discuss the role of the HPA axis and its chemical constituents in the context of chronic stress and 
anxiety/depression development. 
2.1.3.2 Glucocorticoids 
The HPA axis is central in stress response mediation. During times of stress, the hypothalamus secretes 
corticotropin-releasing hormone (CRH), which acts on the anterior portion of the pituitary gland. This 
stimulates release of adrenocorticotropic hormone (ACTH), resulting in increased GC production and 
secretion by the adrenal cortex of the adrenal glands. In acute stress, elevated GC levels regulate a number 
of physiological processes that are vital for mediation of “fight-or-flight” responses (Elenkov, 2008; Padgett 
and Glaser, 2003), such as metabolism, immune function, cardiovascular function, and cognition (Oakley and 
Cidlowski, 2013). 
The actions of GCs are mediated by binding to the widely-distributed glucocorticoid receptor (GR). Negative 
feedback mechanisms regulate HPA axis activity via GC binding to mineralocorticoid receptors (MRs) localised 
in the hippocampus, and GRs. GR binding terminates physiological responses to the acute stressor, facilitating 
restoration of homeostatic balance (Haddad et al., 2002). In chronic stress, adaptations occur in response to 
continual GC release, with downregulation of GR expression, resulting in increased activity in the MR system; 
this results in pathological hyperactivation of the HPA axis (Figure 2.2). 




Figure 2.2: The hypothalamic-pituitary-adrenal axis physiology in acute stress, and maladaptations in 
response to chronic stress. A self-perpetuating cycle exists between chronic stress and HPA hyperactivity, 
through the products of hypercortisolaemia (redrawn and modified from Elenkov (2008), Flandreau et al. 
(2012), and Stokes (1995)) 
Downregulation of GR expression in circulating leukocytes results in an inability for GCs to limit the 
inflammatory response. Since an immune challenge that threatens homeostasis can be regarded as a 
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inflammatory stress. Continuous inflammatory insults result in hypercortisolaemia, exacerbating systemic GR 
expression downregulation in chronic stress. 
Constantly elevated circulating GC levels means that the physiological stress response is always activated. In 
a normal “fight-or-flight” situation, gluconeogenesis occurs to provide energy for increased metabolism and 
muscle functionality, the results of which are an increase in blood-glucose levels, heart rate and blood 
pressure. Continual gluconeogenesis causes chronic hyperglycaemia, hypertension, cardiovascular 
complications such as arrhythmia and hypercoagulation, and insomnia (MacLaughlin et al., 2011; Oakley and 
Cidlowski, 2013). These conditions are precursors to the development of lifestyle illnesses such as 
neurodegeneration and T2D which further contribute to systemic inflammation (Elenkov, 2008), with pro-
inflammatory cytokines feeding back into the HPA axis.  
Having briefly reviewed the general literature on role players involved in major stress-immune cross-talk, the 
next section will focus more specifically on the role of the serotonergic system and its links to the 
inflammatory immune system in the setting of chronic stress. 
2.1.3.3 Serotonin 
Serotonergic dysfunction is a central focus in the pathophysiology, as well as the treatment of, anxiety and 
depression (Sorgdrager et al., 2017). Exposure to chronic stressors results in reduced 5-HT availability in the 
prefrontal cortex, reflecting a state in which synthesis of 5-HT is outpaced by release (Charney and Drevets, 
2002). These effects are also observed in circulating blood platelets, where 5-HT release occurs more rapidly 
than 5-HT reuptake, resulting in haematological and immunological disorders that will be discussed in 
subsequent sections. 
The serotonin transporter (SERT) plays a fundamental role in the maintenance of serotonergic function, by 
regulating 5-HT uptake into cells (Hoirisch-Clapauch et al., 2014; Velenovská and Fišar, 2007). SERT is found 
in cells in both the peripheral and central compartments, mainly those of the gastrointestinal tract, platelets 
and serotonergic neurons (Dürk et al., 2005; Hoirisch-Clapauch et al., 2014; Scharinger et al., 2014). 
SERT is a membrane integral glycoprotein, and a member of the SLC6 gene family of Na+/Cl—dependant 
transporter proteins (Hoirisch-Clapauch et al., 2014). The 5-HT uptake process involves its binding to the 
recognition site on SERT, and its transport across the membrane in conjunction with a Na+ ion. The second 
step involves the translocation of K+ across the membrane to the exterior of the cell. The requirement for K+ 
is unique to SERT within the SLC6 family (Jedlitschky et al., 2012).  
Apart from transmission, the synthesis of neurotransmitters in the CNS is another important consideration, 
as their inhibited or upregulated synthesis may also have undesired effects. 5-HT synthesis is dependent on 
the availability of its precursor amino acid, tryptophan. Two major pathways metabolise tryptophan: the 
Stellenbosch University  https://scholar.sun.ac.za
12 
 
kynurenine pathway, regulated by the enzyme indoleamine 2,3-dioxygenase (IDO), and the 5-HT pathway, 
which is initiated by the tryptophan 5-monooxygenase enzyme (Dantzer et al., 2008). 
In this context, inflammation was shown to have a role in pathology. IDO enzymes in macrophages and T-
lymphocytes, assist in degradation of tryptophan to generate kynurenines and kynuramines. These 
compounds function in negative feedback loops to modulate 5-HT-mediated inflammation, as well as pro-
inflammatory molecules (Arreola et al., 2015; Greeson et al., 2015). Therefore, the constant presence of 
circulating pro-inflammatory cytokines reduces tryptophan availability in the CNS, and ultimately 5-HT 
availability (Figure 2.3).  
 
Figure 2.3: Cytokines stimulate catabolism of tryptophan into kynurenine and quinolinic acid via induction of 
IDO, resulting in decreased availability of tryptophan for 5-HT synthesis via tryptophan hydroxylase (TPH). 
Cytokines also induce neopterin synthesis by activated macrophages via guanosine triphosphate 
cyclohyrdolase-1 (GTP-CH1) (Capuron et al., 2003) 
The chronic shunting of tryptophan into the kynurenine pathway is associated with the aetiology of anxiety 
and depressive disorders, as formulated in the monoamine hypothesis of depression (Miura et al., 2008; 
Schiepers et al., 2005; Sorgdrager et al., 2017). 
Stellenbosch University  https://scholar.sun.ac.za
13 
 
The literature reviewed up to this point provides clear evidence of the neuro-immune crosstalk, as well as its 
maladaptation, involved in progression towards chronic disease. It is clear that in the context of anxiety, 
inflammation and compromised 5-HT availability are central to this maladaptations, and thus clear 
therapeutic targets. However, before treatment options can be considered or evaluated, I would like to 
briefly discuss a novel potential model with which to investigate modulations of neuro- and immune role 
players.  
Blood platelets are known to secrete 5-HT, although this action is usually assessed as an indicator of platelet 
activation in hypercoagulability studies. However, more relevant to the context of the current thesis, the next 
section discusses the feasibility of using platelets as a model for the serotonergic system in the context of 
depression/anxiety research. 
 Platelets to model the central serotonergic system in anxiety? 
Available techniques to study brain function depend on neuroimaging techniques – which rely on indirect 
markers of activation (Oathes et al., 2015) – and post-mortem examination, which presents with major 
limitations. Even though these techniques have provided valuable insight into affected brain regions in 
anxiety and depression, they do not elucidate the array of mechanisms involved in the development of these 
chronic mental disorders (Ressler and Mayberg, 2007). Given the close links between the immune and 
serotonergic system, it may be possible to employ more accessible samples to model the serotonergic 
system, both for diagnostic and therapeutic monitoring assessments. 
As previously mentioned, 5-HT is best known as a neurotransmitter involved in mood-related disorders. 
However, it is also responsible for mediating platelet aggregation via the 5-HT receptor 5-HT2A. In addition, 
in the context of haemostasis, it acts on endothelial cell receptors and elicits production of nitric oxide 
specifically in undamaged cells, which controls the extent of coagulation by vasodilation and inhibition of 
platelet aggregation, so that clot formation is restricted to damaged areas only  (Jedlitschky et al., 2012).  
More directly relevant to the thesis topic of immune-stress cross-talk, platelet 5-HT has been shown to 
modulate the inflammatory response (Mumford et al., 2015), the mechanisms of which will be discussed 
later in this section. Therefore, it is of interest to understand the role of the platelet in 5-HT turnover. 
Platelets are small cell fragments of megakaryocytes, found in circulation at a density of 150-450 x 109/litre 
of blood. Although they are anucleate, they perform a great number of functions, mainly involved in the 
maintenance of vascular integrity through sensing injury to blood vessel endothelium, accumulating at a site 
of damage, and subsequently causing blood clotting to close the wound and promote tissue repair 
(Jedlitschky et al., 2012; Scull et al., 2010).  
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In addition to their secretory products, platelets also possess several immune receptors on their surface, 
including toll-like receptors and immunoglobulin receptors (Duerschmied et al., 2014; Gawaz et al., 2005; 
Starossom et al., 2015). The proposed mechanism by which platelets achieve immunomodulation is through 
their direct interaction with cells of the innate immune system (Gawaz et al., 2005; Speth et al., 2013). 
Upon activation, platelets undergo a series of morphological changes, including shape change and membrane 
budding, granular content release, adhesion and aggregation. Measures of platelet activation utilise these 
changes, which are assessed either directly (scanning electron microscopy, flow cytometry) or indirectly by 
measuring metabolites of activated platelets in plasma or urine (ELISA) (Choudhury et al., 2007).  
2.2.1 Platelet granules 
Platelets contain mRNA as well as the full translation machinery required for protein synthesis. These 
proteins are then stored in lysosomal granules (≤3 per platelet), dense bodies (or δ-granules) (3-8 per 
platelet) and α-granules (50-80 per platelet) (Duerschmied et al., 2014; Speth et al., 2013). Platelets maintain 
normal haemostasis by releasing granule contents at sites of vascular damage (Ambrosio et al., 2012; 
Jedlitschky et al., 2012; Jonnalagadda et al., 2012; Smyth et al., 2009). A summary of the main constituents 
of each granule type is presented in Table 2.3. 
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Table 2.3: Platelet granules and corresponding contents 





von Willebrand factor 









Platelet-derived growth factor 
TGF-β 
Endothelial cell growth factor 
Epidermal growth factor 
Insulin-like growth factor-1 
Vascular endothelial growth factor 
Albumin 
Immunoglobulins 




























(Ambrosio et al., 2012; Gros et al., 2015; Koudouovoh-Tripp and Sperner-Unterweger, 2012; Mumford et 
al., 2015; Smyth et al., 2009) 
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Platelet δ-granules are responsible for the storage of 5-HT, the accumulation of which is derived from 
overflow of its production by enterochromaffin cells of the digestive tract (Jedlitschky et al., 2012; Mumford 
et al., 2015). In addition, δ-granules act as storage sites for  pyrophosphates, calcium, adenosine diphosphate 
(ADP) and adenosine triphosphate (ATP) (Ambrosio et al., 2012; Gobbi et al., 2003; Jedlitschky et al., 2012; 
Mumford et al., 2015). The contents of these granules are essential  for mediation of sustained platelet 
activation; the importance of their involvement is evident in patients with bleeding disorders as a result of a 
deficiency in δ-granules, or their contents (Jonnalagadda et al., 2012).  
The membrane proteins of δ-granules include CD63, which increases on the outer surface of platelets 
following their exocytosis, as well as those responsible for turnover of δ-granules content, such as the ADP 
transporter and vesicular monoamine transporter-2 (VMAT-2).  
Platelet lysosomes contain the enzyme β-hexosaminidase, as well as other acid glycohydrolases (Ambrosio 
et al., 2012). The role of their release remains unclear, although it is hypothesised that lysosomal enzymes 
could be important in thrombus remodelling and host defence (Jedlitschky et al., 2012; Jonnalagadda et al., 
2012; Mumford et al., 2015). 
Platelet granule release requires regulated synthesis of each granule type, in conjunction with a multi-step 
secretion pathway that comprises of the following components: (i) agonist interaction with surface receptors 
on the platelet, (ii) intracellular signalling, (iii) alterations in intracellular levels of calcium, phosphates and 
kinases, (iv) remodelling of the cytoskeleton and finally (v) fusion of the granule and platelet membranes that 
results in the release of the granule contents (Mumford et al., 2015). A diagrammatic representation of this 
process can be seen in Figure 2.5. 
When granules are exocytosed upon platelet activation, integral membrane proteins are inserted into the 
plasma membrane, altering its composition. Therefore, activated platelets exhibit extra surface markers, 
such as P-selectin, CD63 and integrin αIIbβ3 (Jonnalagadda et al., 2012; Smyth et al., 2009). The exposure of 
P-selectin (CD41a) is important for platelet-leukocyte interaction, which will be discussed in the next section. 
Stimulation of platelets with low concentrations of weak agonists, such as ADP, results in a greater α-granule-
δ-granule release ratio. However, stimulation with strong agonists (such as monoamine-releasing agents) 
appears to reverse this ratio (Jonnalagadda et al., 2012). 
2.2.2 Platelet modulation of the inflammatory response 
The human inflammatory response is highly regulated by an intricate network of control factors. Among 
these regulatory components, cytokines are most prominent. A dynamic balance exists between pro- and 
anti-inflammatory cytokines, and under pathological conditions, anti-inflammatory cytokines may not 
provide sufficient control over pro-inflammatory activities, resulting in a systemic pro-inflammatory state 
(Opal and DePalo, 2000; Poon et al., 2015). 
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It has been shown that platelets contribute to inflammation in a number of conditions including infections, 
and in chronic inflammatory disease (Duerschmied et al., 2014; Gawaz et al., 2005; Smyth et al., 2009). Since 
platelets, upon activation and adhesion, secrete cytokines, chemokines, and other mediators of inflammation 
stored in their α- and δ-granules, they possess the capacity to initiate, modulate, propagate and resolve the 
inflammatory response (Gros et al., 2015).  
Platelets possess the ability to regulate most effector functions of neutrophils and macrophages, such as 
reactive oxygen species (ROS) production, secretion of neutrophil granule content, and phagocytosis 
(Duerschmied et al., 2014). Evidence of direct contact between platelets and neutrophils/monocytes via P-
selectin is also important for the oxidative burst required for activation (Gros et al., 2015).  
Additionally, while some platelet-derived factors target leukocytes such as neutrophils and monocytes 
directly, others like 5-HT and platelet-activating factor also act on platelets themselves, thus amplifying their 
regulatory effects on leukocyte recruitment. The relationship between platelets and major leukocytes in the 
inflammatory response, can be seen in Figure 2.4. 
 
Figure 2.4: Platelet-platelet and platelet-leukocyte interaction in the inflammatory response (redrawn and 
modified from Duerschmied et al. (2014) and Gros et al. (2015)) 
The immunomodulatory ability of platelets is important in the setting of chronic stress, since we now know 
that it is characterised by hyperresponsiveness of the stress-immune pathways, which also affect platelet 
functionality. Since platelet activation involves secretion of 5-HT, chronic stress results in hypersecretion of 
platelet 5-HT stores. 5-HT is an important activator of the clotting cascade in response to injury; thus, an 
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excess of 5-HT in circulation stimulates chronic platelet activation via 5-HT2A, which subsequently causes 
blood hypercoagulability and elevated cytokine secretion. 
The consequences of chronic platelet activation feed back into the complex cycle of stress-immune crosstalk, 
contributing to the development of chronic inflammatory disease and anxiety/depression. Since platelets are 
affected so similarly to serotonergic neurons in this cycle, they have been used as a model for the central 
serotonergic system in a number of studies, specifically for the study of coagulation in chronic inflammatory 
illness (Hüfner et al., 2014; Silić et al., 2012; Soma et al., 2016; Van Rooy and Pretorius, 2015) and to better 
understand 5-HT dynamics (Gobbi et al., 2003; Ramström et al., 1999), sometimes in response to anxiolytic 
or anti-depressive treatments (Born et al., 1980; Gawaz et al., 2005; Jedlitschky et al., 2012; Reikvam et al., 
2012). The next section will highlight the major similarities between platelets and serotonergic neurons and 
indicate their diagnostic potential in anxiety/depression therapeutics. 
2.2.3 Structural similarities between platelets and serotonergic neurons 
2.2.3.1 Serotonin uptake and storage  
5-HT uptake by platelets is the primary mechanism of 5-HT clearance from the blood. The key difference 
between platelets and serotonergic neurons, is the inability for platelets to produce 5-HT (Charnay and Léger, 
2010; Jacobs and Azmitia, 1992). While 5-HT is synthesised and then stored in vesicles within serotonergic 
neuron axons and terminal buds, 5-HT storage in platelet δ-granules results from a two-step process: (i) the 
uptake of 5-HT across the plasma membrane via SERT, and (ii) transport across the δ-granule membrane via 
VMAT-2. SERT and VMAT-2 are also present in serotonergic neurons and are responsible for reuptake of 
released 5-HT from the synaptic cleft to limit duration and magnitude of 5-HT signalling, and for 5-HT uptake 
and storage in neuronal vesicles, respectively. Transport via VMAT-2 is facilitated by an electrochemical 
proton gradient across the dense body membrane, which is established by vacuolar H+-ATPase (Jedlitschky 
et al., 2012). 
Platelets also possess uptake mechanisms for certain amino acid transmitters such as γ-aminobutyric acid, 
aspartate, glutamate and glycine. Uptake of these factors resembles that of neurons in the CNS (Rainesalo et 
al., 2005) – this further qualifies platelets as a model system for the central serotonergic system. 
2.2.3.2 Serotonin release and receptors 
The release of 5-HT by platelets promotes platelet functions via the 5-HT receptor, 5-HT2A. When platelets 
adhere and aggregate at a site of vessel injury, 5-HT is released, which directly accelerates platelet 
aggregation and vasoconstriction, and potentiates the response of platelets to other agonists such as 
adenosine diphosphate, collagen, and thromboxane A2 (Hoirisch-Clapauch et al., 2014; Jedlitschky et al., 
2012).  
Sustained stimulation of platelet 5-HT receptors by elevated circulating 5-HT results in receptor 
desensitization and decreased expression. Likewise, excess 5-HT in the CNS acts as negative feedback on 
Stellenbosch University  https://scholar.sun.ac.za
19 
 
autoreceptors on serotonergic neuron terminals, decreasing both 5-HT release by presynaptic neurons and 
decreased receptor expression on postsynaptic serotonergic neurons (Charnay and Léger, 2010). These 
alterations may be responsible for the delayed response to anxiolytic or antidepressant treatment in some 
patients. 
The major similarities between platelets and central serotonergic neurons are summarised in Figure 2.5. 
 
Figure 2.5: Key structural similarities between (A) central serotonergic neurons and (B) platelets (redrawn and 
modified from Jedlitschky et al. (2012)) 
2.2.3.3 Platelets in anxiety/depression 
Not only are platelets activated by agonists (ADP, calcium, heparin etc) and physical stress, but also by mental 
stress (Koudouovoh-Tripp and Sperner-Unterweger, 2012), highlighting another link between platelets and 
central serotonergic neurons. Catecholamines, the main neurotransmitters in the SAM axis, activate platelets 
via adrenergic receptors. HPA axis hyperactivity has also been shown to stimulate platelet 5-HT release, as 
well as increase pro-inflammatory cytokine secretion (Leonard, 2014). Additionally, platelets are activated 
by certain lifestyle factors that contribute to chronic systemic inflammation, such as smoking, excess alcohol 
and drug use, and poor dietary habits. 
Since chronic stress leading to the development of chronic inflammation and mental health disorders, results 
in 5-HT hypersecretion and downregulation of SERT and 5-HT receptors (Maes et al., 2011, 1998; Silić et al., 
2012), one would expect to observe similar effects in peripheral blood platelets isolated from anxious or 
depressed individuals. This supports the idea that platelets could potentially be employed as an easily 
accessible, effective model with which to diagnose anxiety type (acute vs chronic) or depression status, based 
on maladaptations in intraplatelet 5-HT levels and receptor expression. These parameters may also prove 
useful in determining disease progression and potential targets for treatment. 
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Staying with the scope of this thesis, depression and anxiety disorders are most often treated with 
pharmaceuticals aimed at increasing either 5-HT levels, or duration of its synaptic availability, or both. More 
recently, some focus has also been on natural products with demonstrated central bioavailability. In the next 
few sections, I provide an overview of the most common pharmaceutical treatment types and their 
mechanisms of action, followed by a short reference to one natural product that we have been studying in 
this context for many years. 
 Therapeutic interventions 
The inflammation associated with anxiety and depression is attenuated by anxiolytic and antidepressant 
drugs (Abdel-Salam et al., 2004; Sawynok et al., 2001). Conversely, clinical evidence has shown that non-
steroidal anti-inflammatory drugs such as cyclooxygenase-2 (COX-2) inhibitors and infliximab exert anti-
depressive effects, and have even been found to enhance the therapeutic response when administered in 
combination with antidepressants (Krause et al., 2012; Müller, 2010). 
The bi-directional effects of anxiolytics/antidepressants are of great interest in the context of chronic 
inflammatory disease, where a self-propagating cycle exists in terms of inflammation and illness. Two of the 
major classes of drugs employed in the attempted treatment of anxiety and depressive disorders are SSRIs 
and MRAs. The beneficial effects of these pharmaceuticals will be discussed in the following sections. 
2.3.1 Selective serotonin reuptake inhibitors and monoamine-releasing agents 
2.3.1.1 Serotonergic system modulation by serotonin reuptake inhibition 
Inhibition of 5-HT uptake was first related to antidepressant actions in 1975 by Wong et al. However, the first 
pharmaceuticals designed to target reuptake also targeted 5-HT receptors, causing adverse effects such as 
sedation and cardiac arrest (Hiemke and Härtter, 2000). Therefore, the development of safer drugs that 
exclusively blocked 5-HT uptake was of great priority.  
Consequently, SSRIs – which have high affinity for SERT and low affinity for receptor sites  – were developed 
(Duerschmied et al., 2014, Hoirisch-Clapauch et al., 2014), and are among the most prescribed drugs today 
(Gobin et al., 2014). Although SSRIs have better overall safety and tolerability than older counterparts, their 
side-effects include sexual dysfunction, sleep disturbance and weight gain (Hiemke and Härtter, 2000; Millan, 
2004). 
Citalopram has shown to have the highest selectivity for SERT out of all SSRI medications (Hiemke and 
Härtter, 2000), and has been used to treat conditions ranging from minor to major depression, anxiety, panic 
disorders, and obsessive-compulsive disorders (Gobin et al., 2014). In blocking 5-HT reuptake from synaptic 
clefts within the CNS, SSRIs exert their effects by facilitating longer 5-HT availability and increased receptor 
binding (Matthäus et al., 2016). This is beneficial in the context of 5-HT depletion due to hypersecretion, 
where both 5-HT concentration and receptor expression are low. 
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Importantly, patients on SSRI treatment have been found to be at increased risk for abnormal bleeding, but 
at decreased risk of arterial occlusive events (Hoirisch-Clapauch et al., 2014; Jedlitschky et al., 2012; Reikvam 
et al., 2012), due to the fact that SSRIs prevent platelet 5-HT uptake via SERT. This ultimately decreases 
platelet-platelet communication in the context of activation for coagulation purposes. In human studies, all 
SSRIs have shown a significant decrease in platelet 5-HT content after several weeks of treatment, reaching 
levels below ±10% of the pre-treatment levels (Hoirisch-Clapauch et al., 2014). 
2.3.1.2 Anti-inflammatory properties of SSRIs 
In vitro studies with human whole blood have shown that SSRI antidepressants inhibit the production of pro-
inflammatory cytokines IL-1, -2, and -6, and TNF-α, while stimulating the secretion of IL-10 (Berk et al., 2013; 
Gobin et al., 2014; Leonard, 2014; Maes et al., 1997). These effects are independent of the action of SSRIs on 
SERT, the mechanisms of which will be discussed next. 
A proposed mechanism of action behind the anti-inflammatory effects of SSRIs is the inhibition of interferon-
γ secretion, which in turn impedes the influx of calcium ions into immune cells. Calcium is necessary for the 
activation of the JAK-STAT pathway; thus, reduced activation of this pathway results in decreased release of 
pro-inflammatory cytokines (Leonard, 2014).  
Studies performed on various SSRIs noted the following: (i) long-term administration in rats attenuated LPS-
induced depressive behaviour and neuroendocrine alterations; (ii) administration of sertraline is 
accompanied by attenuation of inflammatory response activation, which was indicated by reduced pro-
inflammatory cytokine levels; (iii) chronic treatment with imipramine demonstrated a reduction in immune 
activation in rats subjected to a chronic, mild stress model of depression (Schiepers et al. 2005).  
2.3.1.3 Monoamine-releasing agents 
Despite the improved safety profiles of current SSRIs, several weeks of administration are required prior to 
the expression of beneficial effects, since therapeutic efficacy relies on alterations in receptor density and 
serotonergic neurogenesis (Millan, 2004). A reduction in undesired side effects is also of importance, as these 
compromise compliance and interfere with the therapeutic outcomes of SSRI treatment (Hiemke and Härtter, 
2000). 
Attenuation of low 5-HT signalling dynamics may also be achieved through increasing 5-HT:SERT and 5-
HT:receptor ratios. MRAs, capable of altering this ratio, are considered the third – and most recent – 
generation of antidepressants. MRAs have been shown to have improved tolerability, increased efficacy, 
shorter delay in clinical efficacy, and effective anxiolytic and antidepressant effects (Millan, 2004). 
MRAs enhance SERT-mediated exchange and release of 5-HT, by shunting available tryptophan into the 
tryptophan hydroxylase pathway, resulting in greater 5-HT synthesis (Capuron et al., 2003). In addition, MRAs 
prevent uptake of 5-HT into storage vesicles, through inhibition of VMAT-2, and cause release of this 
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neurotransmitter through reverse-transport at VMAT-2 (Simantov, 2004).  Some potent MRAs, such as 
methamphetamines, are also capable of binding to SERT, which further potentiates the effects of 5-HT as 
discussed previously (Simantov, 2004). 
Overlooking the adverse effects of SSRIs, one can appreciate the therapeutic potential of a drug that 
possesses both mild MRA and mild SSRI properties, as it may provide immediate beneficial effects through 
5-HT release while neuronal plastic remodelling occurs under the influence of SSRI treatment. In addition, 
the synergistic effects of monoamine release, together with 5-HT reuptake inhibition, may lend itself to 
greater beneficial outcomes in terms of treatment of mental health disorders as well as chronic stress-
induced inflammation. A summary of the targets of these common antidepressants/anxiolytics in the 
complex cycle of chronic stress and chronic inflammatory disease can be seen in Figure 2.6.  
 
Figure 2.6: Therapeutic targets of SSRIs and MRAs in the treatment of chronic stress-induced inflammatory 
disease 
The last section of this review highlights the therapeutic potential of Sceletium tortuosum in the context of 
inflammatory mental health disorders and chronic inflammatory disease. 
2.3.2 Sceletium tortuosum 
Sceletium tortuosum, known as kanna in Nama and kougoed in Afrikaans, has one of the oldest histories of 
use of any South African medicinal plant (Gericke and Viljoen, 2008; Shikanga et al., 2012). The earliest 
written records of Sceletium tortuosum use date back to 1662 and 1685 (Murbach et al., 2014). The plant is 
most commonly chewed but can also be consumed as a tea or snuff and smoked. It was originally used by 
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indigenous people for toothache, and relief from hunger and abdominal pain (Loria et al., 2014; Shikanga et 
al., 2012).  
In the western setting, Sceletium tortuosum first gained popularity due to anecdotal claims of mood-
elevating, anxiolytic properties, especially following fermentation of the plant material (Patnala and Kanfer, 
2009; Smith et al., 1996). Scientific investigation of these claims has shed light on the mechanisms of action 
behind Sceletium’s effects on the CNS. This section will highlight the main findings from major studies 
involving a high-mesembrine (Figure 2.7) Sceletium tortuosum extract (Trimesemine™) and indicate further 
research areas to elucidate exact effects and mechanisms of action of this traditional medicine.  
 
 
Figure 2.7: The four major alkaloids that define the alkaloid composition of Sceletium tortuosum (modified 
from Patnala and Kanfer (2009)) 
Mesembrine is one of the most pharmacologically-active alkaloidal components of Sceletium tortuosum, and 
was recently shown to possess cytoprotective and mild anti-inflammatory properties in the setting of acute 
inflammation in the peripheral compartment, completely inhibiting the approximately 40% loss in monocytic 
cell viability after exposure to LPS and limiting pro-inflammatory cytokine production in this context, although 
not inhibiting it entirely (Bennett and Smith, 2018). In addition, Trimesemine™ was found to directly 
modulate adrenal steroidogenesis, effectively inhibiting glucocorticoid production (Swart and Smith, 2016). 
These in vitro findings indicate that Sceletium supplementation may be beneficial in the context of chronic 
inflammation-related illnesses. 
In terms of central action of the plant, we have shown that Trimesemine™ exerts anxiolytic effects in a rat 
model of psychological stress (Smith, 2011). These effects were confirmed in a rat model of nociception, 
anxiety, depression and ataxia (Loria et al., 2014), where Sceletium extract supplementation was found to 
exert beneficial effects in terms of mood elevation and decreased nociceptive responses, when compared to 
suitable SSRI and MRA controls.  
Δ7-mesembrenone mesembrenone mesembranol mesembrine 
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The effect of the Sceletium tortuosum has, to date, been tested in a few human clinical trials (Nell et al., 2013; 
Smith et al., 1996; Terburg et al., 2013). In a recent placebo-controlled clinical trial, unsolicited positive 
comments from individuals supplemented with a commercial Sceletium extract, Zembrin®, included feeling 
generally “better”, coping well with stressful situations, and improved sleep at night. The study showed that 
doses of 8mg and 25mg, taken once daily for three consecutive months, were well tolerated by the human 
body in the context of physical examination and laboratory assessments (haematology, urinalysis and 
biochemistry) and the recording of adverse events (Nell et al., 2013). However, it was stated that further 
clinical studies should be conducted to investigate the effects of Sceletium on cognitive function, anxiety and 
mood. Subsequently, another paper on the same product reported attenuated amygdala reactivity to fearful 
faces after a single dose of low-mesembrine Sceletium extract (Terburg et al., 2013). 
A recent in vitro study by our group in human astrocytes and mouse hippocampal cells further elucidated the 
mechanisms of action behind the anxiolytic effects of Trimesemine™, indicating that it acts primarily as an 
MRA, which suggests that the more frequently reported SSRI function may be a secondary mechanism 
(Coetzee et al., 2016). These results, in addition to the confirmed anti-inflammatory effects of Trimesemine™, 
indicate that this plant extract is ideal for studying the serotonin-immune link, allowing for more detailed 
interpretation of generated data. 
The promising effects elucidated for a high-mesembrine Sceletium tortuosum extract warrant further 
research into the other major alkaloids present in the plant. Preliminary research by our group using a high 
Δ7-mesembrenone extract has shown potential anti-cancer effects (unpublished data). Since the relationship 
between inflammation and cancer is well known (Colotta et al., 2009; Dhabhar, 2009; Mantovani et al., 2008; 
Reiche et al., 2004), this further supports the anti-inflammatory potential of Sceletium tortuosum. 
Sceletium tortuosum’s apparent immunomodulatory properties may be attributed to many mechanisms. 
Firstly, changes in immune activity and cytokine production after treatment may be secondary to changes in 
neurotransmitter activity, as brain-immune communication occurs through monoaminergic signalling (Basu 
and Dasgupta, 2000; Gobin et al., 2014). Secondly, Sceletium may attenuate cytokine-induced alterations in 
GC receptor expression, thereby ceasing cytokine-induced GC resistance in both the hypothalamus and 
pituitary gland (Carvalho and Pariante, 2008; Kiecolt-Glaser et al., 2015). In doing so, Sceletium may restore 
GC-mediated negative feedback inhibition of the HPA axis. A final mechanism by which Sceletium may reverse 
the central effects of cytokines may be through inhibition of cytokine-induced indoleamine-2,3-dioxygenase 
activation (Arreola et al., 2015; Capuron et al., 2003; Dahl et al., 2014). As mentioned previously, 
overstimulation of indoleamine-2,3-dioxygenase by cytokines has been implicated in HPA-axis and 5-HT 
disorders associated with mental health disorders. 
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From this data, I conclude that Sceletium extract in moderation is safe for human consumption. Furthermore, 
in light of all the much-desired effects it may affect in individuals afflicted with anxiety and/or depression, 
the therapeutic potential of this plant should be further developed. 
 Hypothesis and Aims 
I hypothesised that a high-mesembrine and high-Δ7 mesembrenone Sceletium tortuosum extract will 
beneficially modify both the inflammatory immune system and the serotonergic system, in the context of 
chronic stress-related disorders. Secondly, I hypothesised that peripheral blood platelets are a suitable model 
of the central serotonergic system in this context. 
To test this hypothesis, the following aims were formulated: 
 Evaluation of the immunomodulatory properties of Sceletium tortuosum in the central nervous 
system 
 Assessment of the suitability of the platelet model to mimic the serotonergic system 
 Elucidation in more detail, the manner in which Sceletium tortuosum relieves anxiety via modulation 
of neuro-immune crosstalk  
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Chapter 3 – Experiment I 
In this chapter, I present data in manuscript format, as submitted for publication in Journal of Physiology and 
Biochemistry (Impact Factor 2.44).  I was invited to write this manuscript for a special issue, following 
presentation of these data at an international conference in 2017 (Conferences on Trans-Pyrenean 
Investigations in Obesity and Diabetes: 14th French-Spanish Meeting). Although the journal invitation 
specified obesity as context for data presentation, these data is also relevant to other inflammatory 
conditions, such as anxiety. 
At this point, I would like to acknowledge two international collaborators – Prof Victor López and his MSc 
student Arno van Camp (University San Jorge, Zaragoza, Spain) – for their contribution to this paper. I 
completed the astrocyte experiments, while they contributed their data on neural enzyme inhibition by the 
extracts used. 
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Sceletium tortuosum may delay chronic disease progression via alkaloid 
dependant antioxidant or anti-inflammatory action 
Bennett ACa, Van Camp Ab, López Vb, Smith Ca* 
a Department of Physiological Sciences, Science Faculty, Stellenbosch University, Stellenbosch, South Africa  
b Department of Pharmacy, Faculty of Health Sciences, San Jorge University, Villanueva de Gállego, Zaragoza, 
Spain 
Abstract 
The link between obesity-induced systemic inflammation and decreased insulin signalling is well-known. It is 
also known that peripherally-produced inflammatory cytokines can cross the blood-brain barrier, resulting in 
the release of neurotoxins that can ultimately lead to demise of central nervous system integrity. A high-
mesembrine Sceletium tortuosum extract was recently shown to possess cytoprotective and mild anti-
inflammatory properties in monocytes and to target specific p450 enzymes to reduce adrenal glucocorticoid 
synthesis.  This is significant since the aetiology of both obesity and diabetes is linked to inflammation and 
excess glucocorticoid production. Given the interlinked nature of glucocorticoid action and inflammation, 
central immunomodulatory effects of two Sceletium tortuosum extracts prepared by different extraction 
methods were investigated.  Human astrocytes were pre-treated for 30 minutes, before exposure to 
Escherichia coli lipopolysaccharide for 23.5 hours (in the presence of treatment). Cytotoxicity, mitotoxicity 
and cytokine responses (basally and in response to inflammatory stimulus) were assessed. In addition, total 
polyphenol content, antioxidant capacity and selected neural enzyme inhibition capacity were assessed for 
both extracts. The high-mesembrine Sceletium extract exerted cytoprotective and anti-inflammatory effects. 
In contrast, the high Δ7-mesembrenone extract, rich in polyphenols, exhibited potent antioxidant effect, 
although with relatively higher risk of adverse effects with overdose. We conclude that both Sceletium 
tortuosum extracts may be employed as either a preventative supplement or complimentary treatment in 
the context of obesity and diabetes; however, current data also highlights the impact that extraction methods 
can have on plant product mechanism of action.  
  




The prevalence of diabetes worldwide is predicted to reach 366 million by 2030 (Wild et al., 2004). The major 
focus of diabetes management is glycaemic control, which commences relatively late in the developmental 
time frame of the disease. In contrast, oxidative stress and chronic systemic inflammation are present much 
earlier and responsible for the development of widespread insulin resistance, ultimately resulting in the 
establishment of type 2 diabetes (T2D) (Shoelson et al., 2006).   
In addition, peripheral inflammation is linked to cognitive decline, via crosstalk with neuroinflammatory 
processes. This has been confirmed by multiple studies, which have reported an increased risk of dementia 
associated with obesity (Anstey et al., 2011; Hassing et al., 2010; Nepal et al., 2014). This phenomenon has 
been termed “type III diabetes” (T3D) (De La Monte, 2008) and results from overlapping pathways of 
inflammation, oxidative stress and mitochondrial dysfunction, which form the basis of obesity, type II 
diabetes (T2D), and neurodegeneration (Pugazhenthi et al., 2017; Tucsek et al., 2014). 
T3D results from peripheral inflammation, which triggers neuroinflammatory responses via gene expression 
profiling (Thomson et al., 2014). In addition, inflammation within the CNS is attributed to damage to the 
blood-brain barrier (BBB), resulting from migration of leukocytes into the central compartment. 
Compromised BBB integrity has been observed in conjunction with hippocampal-dependent cognitive 
decline in a rat model of diet-induced obesity (Tucsek et al., 2014). 
Both inflammation and oxidative stress seldom occur in isolation and are characteristic of underlying 
pathology. The relationship between the two is often circular, with no determinable starting point: 
inflammation may cause oxidative stress in some settings, while in other cases, the converse occurs (Belanger 
and Magistretti, 2009). Relevant to the topic of diabetes, antioxidant treatment, have been shown to 
attenuate the harmful effects of high glucose exposure in vitro in a simulated blood brain-barrier model (Allen 
and Bayraktutan, 2009). 
The effectiveness of plant medicines with anti-inflammatory capacity in the context of chronic inflammatory 
disease has also been the focus of many research groups for some time (Ku et al., 2014; Petersen and Smith, 
2016; Williams et al., 2013). One of these potential plant medicines, Sceletium tortuosum, was traditionally 
used by the Khoisan people of Southern Africa for pain relief (Harvey et al., 2011; Patnala and Kanfer, 2013), 
but its commercial availability has significantly increased recently after reports suggest that it may have anti-
depressive and anxiolytic properties (Coetzee et al., 2016; Smith, 2011).  
A high-mesembrine Sceletium tortuosum extract was recently shown to possess cytoprotective and mild anti-
inflammatory properties in the setting of acute inflammation in the peripheral compartment (Bennett and 
Smith, 2018). In addition, it has also been shown to target specific enzymes in the adrenal cortical steroid 
synthesis pathway, to reduce glucocorticoid synthesis (Swart and Smith, 2016).  In the context of diabetes 
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and obesity, this is significant since the aetiology of both conditions is linked to chronically-elevated pro-
inflammatory cytokine and glucocorticoid levels (Hotamisligil, 2006; Pugazhenthi et al., 2017; Shoelson et al., 
2006). 
Given the illustrated benefits which relate to chronic inflammatory diseases such as diabetes, and given 
Sceletium tortuosum’s known psychoactive nature, we hypothesised that the plant could potentially alleviate 
neuroinflammation and central oxidative stress associated with chronic inflammatory illnesses. 
The aims of the current study were therefore, to determine the effects of two different Sceletium tortuosum 
extracts (varying in alkaloidal composition) on human astrocyte viability, both basally and in the presence of 
an acute pro-inflammatory stimulus (Escherichia coli LPS). Furthermore, differences in the functional capacity 
of these neuroimmune cells before and after pre-treatment with Sceletium tortuosum extracts were assessed 
in terms of their capacity for inflammatory cytokine secretion. To further elucidate the mechanisms of action 
by which different Sceletium extracts exert beneficial effects, their inhibition of selected neural enzymes was 
assessed. Antioxidant properties of extracts were assessed in terms of total polyphenol content and 
antioxidant capacity, as well as their effect on astrocyte mitochondrial reductive capacity. 
 Methods and Materials 
3.2.1 Extract preparation and characterisation 
 
Figure 3.1: High-performance liquid chromatography (HPLC) characterisation of the major alkaloids present 
in (A) high-mesembrine extract (extract A) and (B) high-Δ7-mesembrenone extract (extract B) 
The relative composition of each extract can be seen in Figure 3.1, with quantification of relative and total 
alkaloid content presented for comparison in Table 3.1. Extract A is an extract prepared from Sceletium 
tortuosum that was selectively propagated to achieve high mesembrine content, while extract B was more 
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intensively extracted using different solvents, to achieve particularly high levels of Δ7-mesembrenone, which 
is usually contained in very low concentrations in Sceletium plants. Both extracts (batch numbers for extracts 
A and B: DV SCITRI:E 591/016 and DV SCDL7:E 525/016 respectively) were prepared by Verve Dynamics™ 
(Somerset West, South Africa) using proprietary methods and kindly donated by Mr Richard Davies for the 
purposes of this study. 














A 59.81 5.981 59812 68.4 19.8 7.3 
B 16.32 1.632 16317 22.4 11.5 53.2 
AE = Atropine Equivalents 
 
3.2.2 Cell culture 
3.2.2.1 Preparation of treatment media  
A stock solution of each Sceletium extract was made (1mg/ml extract A and 3.7mg/ml extract B), by 
combining extract powder and pre-warmed serum-free media. The mixtures were vortexed for two minutes 
and subsequently sterile-filtered using a 0.22µm syringe filter. From the filtered stock solutions, dilution 
series were performed. 
The total alkaloidal content of extract B was matched to that of A. The high dose of extract A was used to 
represent a supra-physiological dose, while the lower dose has previously shown to be most beneficial in 
similar in vivo models (Coetzee et al., 2016). 
A 2mg/ml LPS (L4391, Sigma Aldrich) stock solution was prepared in Hank’s Buffered Salt Solution (HBSS) and 
added to wells at a final concentration of 20µg/ml for astrocyte inflammatory stimulation. 
3.2.2.2 Cell propagation 
Astrocytes (N7805-100, Life Technologies) of low passage (<5) were thawed and cultured in complete 
Dulbecco’s Modified Eagle Medium (DMEM), containing 10% foetal bovine serum (FBS) and 1% Penicillin-
Streptomycin, and subsequently seeded into a 48-well culture plate at a density of 1 x 104 cells/well in serum-
free DMEM, and incubated (37°C, 5% CO2) for 24 hours to fully adhere to the plate. 
3.2.3  Sceletium extract treatment intervention 
The supernatant was aspirated from each well, and the cell monolayer washed once with Dulbecco’s 
phosphate-buffered saline (DPBS) to remove remaining media residue. A 30-minute pre-treatment period 
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was then initiated, which involved the addition of the different dosages of each Sceletium extract to the 
respective wells. For this period, serum-free media was added to the control and LPS-control groups. 
After the pre-incubation period, LPS was added to the LPS-control wells and LPS-Sceletium combination 
groups, to achieve a final LPS concentration of 20µg/ml. The LPS vehicle was added to all control wells. The 
cells were incubated for a further 23.5 hours. All experiments were performed at least three times, in 
duplicate. 
3.2.4 Propidium iodide viability assay 
A 1mg/ml propidium iodide (PI) (P1304MP, Thermofisher Scientific) stock solution was prepared according 
to manufacturer’s instructions. For a 3µM working solution, the stock solution was diluted 1:500 in 
phosphate buffered saline (PBS). 
Following the 24-hour treatment intervention, supernatant was aspirated from each well. The cell monolayer 
was washed with DPBS before the cells were trypsinized, neutralised and centrifuged at 1500rpm for five 
minutes at room temperature. The resulting supernatant was discarded, and each astrocyte pellet was 
resuspended 1ml PI working solution. The samples were incubated at room temperature for 10 minutes in 
the dark before flow cytometric analysis on BD FACSAria IIu (with BD FACSDiva v8.1 Software). Live stained, 
dead stained, and live unstained controls were included (See Appendix G for a detailed protocol of instrument 
set up, antibody preparation and sample analysis). 
3.2.5 XTT viability assay 
The 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium- 5-carboxanilide (XTT) assay is a commonly 
used test method to indirectly measure cell viability, through assessment of mitochondrial reductive 
capacity. Following the 23.5-hour incubation period, supernatant was removed from each well, centrifuged, 
aliquoted, and stored at −80°C for subsequent batch analysis. 
The astrocyte monolayer was washed twice with DPBS to remove residual Sceletium isolate treatment, 
following which XTT (X4626, Sigma Aldrich) solution (1mg/ml) containing 0.5% phenazine methosulphate 
(P9625, Sigma Aldrich) was added to each well, and a 4-hour incubation period was initiated in a shaking 
incubator at 37°C. Following incubation, optical densities were determined at 490-nm using a Universal 
Microplate Reader (Bio-Tek Instruments, Inc. EL800) and analysed using KCjunior for Windows Data 
Reduction Software (v1.41.3). 
3.2.6 Cytokine measurement  
Cell-free culture supernatant was analysed using a commercial magnetic bead panel assay (custom-designed 
Milliplex MAP Human Soluble Cytokine Receptor Panel, Merck Millipore) for concentrations of IL-6 and 
monocyte chemoattractant protein-1 (MCP-1) (Appendix B). The fluorescent signals were analysed with a 
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Bio-Plex 200 instrument, in conjunction with Bio-Plex Manager 6.1 software. Cytokine responses were 
expressed as absolute concentrations in cell culture supernatant. 
Quantification of cytokine concentrations was performed based on a standard curve, derived from linear 
dilution of the manufacturer-supplied cytokine standards. The detection limit was 0.9pg/ml for IL-6 and 
1.6pg/ml for MCP-1. 
3.2.7 Neural Enzyme Inhibition Assay 
Acetylcholinesterase (AChE) inhibition was measured using a 96-microplate reader based on Ellman’s 
method (Ellman et al., 1961). Tyrosinase inhibition was determined using methods adapted from work by 
Masuda et al. (2005). Appropriate controls were used for all analyses. Data were analysed using GraphPad 
v6 to obtain IC50 values. 
3.2.8 Assessment of anti-oxidant capacity and total phenolic content 
Antioxidant capacity of both extracts were determined using the 2,2-diphenyl-1-picryl-hydrazyl (DPPH) 
inhibition assay, which assesses radical scavenging capacity against DPPH radicals as previously described 
(Cásedas et al., 2017, 2016), with ascorbic acid as reference standard. Total polyphenol content was 
determined by the Folin-Ciocalteu assay, using gallic acid as standard. Total polyphenol content was 
expressed as mg GAE (gallic acid equivalents) per mg of dried extract. 
3.2.9 Statistical Analysis 
Results are presented as averages and standard error of the means (SEMs). Normality of data distribution 
was assessed, followed by non-parametric 2-way ANOVA and LSD post hoc tests. In cases where Levene’s 
test for homogeneity of variances rejected the null hypothesis, the Games-Howell test was used as a post 
hoc test (Statistica v.13.2). Differences were considered significant at p<0.05. 
 Results 
3.3.1 Neuroprotective effects 
The PI exclusion assay illustrated a significant degree of cell death (fewer cells able to exclude the PI stain) in 
astrocytes after exposure to LPS (Figure 3.2). While extract A afforded complete protection in a dose-
dependent manner (Figure 3.2A), extract B was not effective at any dose assessed (Figure 3.2B). It is also of 
interest to note than while extract A did not affect cell viability in the absence of LPS, the highest dose of 
extract B appeared to be cytotoxic.  




Figure 3.2: Cell viability determined by propidium iodide assay, following treatment with (A) extract A or (B) 
extract B with or without LPS stimulation 
3.3.2 Anti-inflammatory outcome 
The response of astrocytes to the extracts, both in presence and absence of an inflammatory stimulus, was 
assessed in terms of two major pro-inflammatory cytokines associated with both neuroinflammation and 
systemic inflammation – IL-6 and MCP-1.  
As expected, LPS exposure elicited significant cytokine responses for both IL-6 and MCP-1 (ANOVA main 
effect, p<0.005 and p<0.0005 respectively). This response was significantly inhibited by extract A, again in a 
dose-dependent manner, with the highest dose tested returning cytokine secretion to basal levels (Figure 
3.3A and B). In contrast, only the lower doses assessed for extract B inhibited the IL-6 response significantly, 
with increasing doses suggesting a relatively more pro-inflammatory outcome (Figure 3.3C). Similarly, the 
MCP-1 response indicated no benefit of extract B at any dose, while higher doses, in fact, elicited an 
inflammatory response similar in magnitude to the one seen after exposure to LPS (Figure 3.3D). 




Figure 3.3: Effect of extract A (A and B) and B (C and D), with/without LPS stimulation, on pro-inflammatory 
cytokine production by human astrocytes 
3.3.3 Neural enzyme inhibition 
The effects of the Sceletium extracts on two enzymes associated with neurodegeneration, namely tyrosinase 
and acetylcholinesterase AChE, were assessed. Both extracts exhibited relatively mild inhibitory effects on 
these neural enzymes when compared to suitable controls (Figure 3.4). Interestingly, while extract A 
exhibited a higher potency for inhibition of AChE than extract B (IC50 0.299 ± 0.34 vs IC50 0.983 ± 0.16 
respectively), the opposite was observed for tyrosinase inhibition (IC50 -1.621 ± 0.75 vs IC50 -0.5908 ± 0.01 
respectively). These results, which suggest as least some degree of neuroprotection – albeit perhaps via 
different pathways for the different extracts – was confirmed by ex vivo exposure of human astrocytes to an 
inflammatory stimulus. 




Figure 3.4: (A) Acetylcholinesterase and (B) tyrosinase inhibition by Sceletium extracts compared to suitable 
standards 
3.3.4 Anti-oxidant outcome 
To investigate whether differences in antioxidant capacity may explain the different effects reported for 
extract A vs. B, antioxidant measures were also assessed. Indeed, total phenolic content of extract B tested 
much higher than extract A (Figure 3.5A). Similarly, while extract B compared favourably to the ascorbic acid 
control in terms of DPPH inhibition, extract A did not appear to have significant antioxidant activity in this 
context (Figure 3.5B).  
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To put this result into a more physiologically relevant context, the LPS assay was again employed, but this 
time, mitochondrial functional capacity was assessed. While extract A did not affect this measure in the 
absence of LPS, extract B significantly compromised mitochondrial reductive capacity at the highest dose 
(Figure 3.5C and D). In fact, this detrimental effect was similar in magnitude to the reduction in cell functional 
capacity after exposure to LPS. Neither extract could maintain mitochondrial function in the presence of LPS.  
 
Figure 3.5: Assessment of antioxidant capacity of extract A and B. (A) total polyphenol content of extracts A 
and B, expressed as gallic acid (GA) equivalents; (B) antioxidant capacity of extracts A and B, compared to 
ascorbic acid; (C) astrocyte mitochondrial reductive capacity following treatment with extract A; (D) astrocyte 
mitochondrial reductive capacity following treatment with extract B 
 Discussion 
The roles of glial cells in CNS homeostasis maintenance and in the regulation of central innate immune 
responses are well documented (Streit et al., 2004; Szelényi, 2001; Wrona, 2006). Astrocytes, which 
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contribute 20-40% of all glial cells, respond vigorously to brain injury, releasing products that can facilitate 
neuronal protection (Kaushal et al., 2015). However, an excessive production of cytokines, chemokines and 
free radicals may result in functional impairment and neuronal decline (Kaushal et al., 2015).  
In terms of the validity of the model employed, it was observed that under control conditions (i.e. at 100% 
viability), astrocytes expressed low levels of IL-6 and MCP-1. This is attributed to a normal physiological 
response to bi-products of functional metabolic processes in the body, as these cytokines are secreted as 
mediators of homeostasis maintenance (Balkwill and Burke, 1989). With exposure to LPS, a significant 
upregulation of cytokine secretion was observed (five-fold and eight-fold for IL-6 and MCP-1 respectively), 
validating sensitivity of the model to reflect an induced, acute inflammatory response. 
When considering effects elicited by the two Sceletium tortuosum extracts assessed, clear differences were 
evident. While astrocyte viability was not affected under basal conditions by either dose of extract A, the 
highest dose of the Δ7-mesembrenone-rich extract B decreased cell viability by 20%. The decrease in viability 
was similar in magnitude to the effect of bacterial LPS exposure. While the latter is an expected response 
due to significant cellular stress caused by a major inflammatory stimulus (Blanco et al., 2005), the effect of 
extract B indicated undesired cell death. Potential reasons for this result were investigated in the context of 
anti-inflammatory and antioxidant mechanisms.  
Firstly, in the context of inflammation, it is important to note that extract A clearly limited endotoxin-induced 
cytokine production to levels that were not significantly different from control conditions. This indicates a 
potential mechanism behind the previously-observed cytoprotective effects of extract A (Bennett and Smith, 
2018). However, the same effects were not seen in response to extract B treatment, which showed that while 
it possessed mild anti-inflammatory properties in lower concentrations (0.037mg/ml and 0.37mg/ml), these 
were not able to limit the inflammatory response to the same extent as extract A. In addition, these effects 
were not conserved for the highest dose of extract B. 
Assessment of neural enzyme inhibition by the extracts shed more light on the differences between the high 
mesembrine versus the high Δ7-mesembrenone extracts.  In terms of AChE inhibition, although relatively 
mild when compared to galantamine, extract A had higher potency than extract B. A major modulator of 
peripheral inflammation is the cholinergic pathway, which involves suppression of innate immune responses 
by acetylcholine. This mechanism inhibits cytokine release by peripheral leukocytes (Gnatek et al., 2012). In 
the CNS, inhibitors of AChE have been shown to enhance the cholinergic anti-inflammatory pathway. 
Previous in vitro studies have shown that acetylcholine pre-treatment inhibited LPS-induced cytokine release 
by microglia (Shytle et al., 2004). Accordingly, AChE inhibitors have shown to limit astrocyte activation and 
cytokine production (Gnatek et al., 2012). This further supports our interpretation that extract A, which is 
high in mesembrine, acts as a mild anti-inflammatory agent (Bennett and Smith, 2018). 
Stellenbosch University  https://scholar.sun.ac.za
38 
 
It was observed that while extract A exerted only mild inhibitory effects in tyrosinase activity, extract B acts 
as a potent inhibitor of this enzyme, matching the effects of kojic acid at higher doses. This effect suggests 
that extract B is more antioxidant in nature, in comparison to extract A. Tyrosinase is a copper-containing 
polyphenol oxidase (i.e. forms part of the reactive oxygen species group), which plays a vital role in melanin 
pigment formation (Kim and Uyama, 2005). Previously, tyrosinase was associated with Parkinson’s disease 
(Chen et al., 2013). Therefore, inhibition of this enzyme may be beneficial in the prevention of 
neurodegeneration.  
The anti-oxidant nature of extract B is further confirmed by assessing its total phenolic content, which was 
20-fold higher than that of extract A. In addition, the DPPH inhibition assay indicated that extract B had a 
similar antioxidant capacity to that of ascorbic acid, a well-documented antioxidant agent (Allen and 
Bayraktutan, 2009). However, it has been reported that antioxidants in high doses may lose their beneficial, 
radical-scavenging properties, and may act as pro-oxidants, causing further cellular damage (Burkitt, 2001). 
Taken together, this suggests that the 20% reduction in cell viability in response to high-dose extract B 
exposure can probably be attributed to antioxidant overload-associated cellular damage. This interpretation 
is in line with the dose-dependent upregulated inflammatory response of the astrocytes exposed to extract 
B which may have been the result of reactive gliosis in response to oxidative damage.  
It was important to assess mitochondrial reductive capacity as an indication of overall cell functionality in the 
setting of Sceletium tortuosum treatment. Mitochondrial dysfunction represents an important link between 
metabolic syndrome and neurodegeneration, and oxidative stress has been well reported in patients with 
neurodegeneration, obesity, and T2D, as well as in rodent models of these conditions (Carvalho et al., 2012). 
Mitotoxicity is an important trigger for inflammation (Sorbara and Girardin, 2011), resulting in the secretion 
of cytokines. 
Our results indicate that while extract A had no effect on mitochondrial reductive capacity in either the 
presence or absence of inflammatory stimulus, treatment with extract B improved this capacity in basal 
conditions. In line with the indicated anti-oxidant properties of extract B, it was noted that a significant loss 
of mitochondrial function occurred with exposure to the highest dose of this extract, again indicative of 
antioxidant overload. Bacterial LPS exposure caused significant mitotoxicity, which was not corrected by the 
addition of either Sceletium extract, indicating that treatment with this natural product may be more 
beneficial in settings of low-grade inflammation, such as chronic disease, rather than in an acute bout of high-
grade inflammation. 
It is becoming increasingly important that a standardised composition of the relevant compounds in 
phytopharmaceutical supplements must be established, from a consumer point of view, as well as for 
regulatory purposes. However, due to the diversity of compounds present in most plants, coupled with 
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varying extraction methods, quality control and standardisation of the pharmacologically-active constituents 
of plant-based supplements is generally not achieved (Patnala and Kanfer, 2013; Shikanga et al., 2012).  
This study highlights the importance of extraction methods effects on extract composition and overall 
properties. While extract A is a less-refined Sceletium tortuosum extract, it appears to exert more beneficial 
effects at a broad range of doses, which is promising in the setting of non-communicable inflammatory 
disease. Although extract B does possess properties that may assist in prevention of chronic inflammation-
associated neurodegeneration, where oxidative stress is both an etiological and comorbid factor, its highly-
refined nature resulted in a much more potent antioxidant product, which needs to be carefully administered 
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Chapter 4 – Experiment II 
In this chapter, data are again presented in manuscript format, as submitted for publication to Journal of 
Affective Disorders (Impact Factor 3.43). However, in addition, since a large portion of effort was invested in 
development of the model, I also present pilot data illustrating the process followed in setting up the platelet 
model elsewhere (refer to Appendix F). 
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Diagnosis and in vitro pharmacological testing in acute and chronic 
anxiety: illustrated relevance of the platelet serotonergic system  
Bennett AC, Smith C* 
Department of Physiological Sciences, Science Faculty, Stellenbosch University, Stellenbosch, South Africa  
Abstract 
Background: Anxiety is characterised by disorders in serotonin neurotransmission. Pro-inflammatory 
cytokines are also responsible for undesired modulation of serotonin signalling, metabolism, and receptor 
expression. Platelets possess structural proteins that are identical to serotonergic neurons. These similarities 
led to the hypothesis that platelets could be employed in diagnosis and therapeutic monitoring of anxiety. 
Methods: Modulators of the serotonergic system – a selective serotonin reuptake inhibitor and a monoamine 
releasing agent (MRA) – were used to investigate the platelet model in anxiety. Isolated platelets from 
anxious and non-anxious subjects were exposed to a known activator (calcium ionophore A23187) and each 
modulator for 15 minutes. Cytokine secretion and changes in platelet serotonergic system activity were 
assessed. 
Results: Basal platelet serotonin levels in individuals exhibiting state/trait anxiety were lower when compared 
to no-anxiety controls (p<0.05), while platelet activation state was increased (significantly lower CD63 
(p<0.05)). Serotonin transporter expression was down-regulated in state anxiety in response to citalopram 
treatment, validating the platelet model. Platelet serotonergic activity reflected differences in modulation of 
the system in terms of serotonin release and reuptake. The MRA – Trimesemine™ – was shown to have anti-
inflammatory effect via modulation of pro- and anti-inflammatory cytokine secretion.  
Conclusions: This study has highlighted key differences between anxious and non-anxious individuals, and 
between state and trait anxiety, in terms of serotonergic system parameters and inflammatory responses, 
suggesting diagnostic potential for the platelet model. Changes in platelet serotonin stores, release and 
reuptake dynamics, and cytokine production indicate that this model is sufficiently sensitive for therapeutic 
monitoring in individuals with anxiety. 
  




Anxiety is currently one of the most common mental disorders, characterised by high levels of emotional 
distress and functional impairment (Baxter et al., 2013; Leal et al., 2017). Two complementary concepts of 
anxiety exist: state anxiety, which refers to psychological and physiological reactions resulting from isolated 
adverse situations, and trait anxiety, which refers to an individual’s personal tendency to present state 
anxiety chronically (Leal et al., 2017). 
This phenomenon of experiencing internal psychological stress in the absence of external stressors results in 
chronic activation of the stress response pathways, the products of which often have detrimental 
consequences for an individual’s wellbeing. The extent and duration of stress-induced alterations in 
glucocorticoids and neurotransmitters have substantial effects on overall psychological health, in addition to 
facilitating a relative pro-inflammatory status (Basu and Dasgupta, 2000; Dhabhar, 2009). It is here where 
individual differences become relevant while studying human models, as stress perception and coping 
methods can have significant effects on the kinetics, peak levels and duration of elevated stress hormones 
and cytokines in circulation (Dhabhar, 2009). 
Enduring psychological stress, such as in anxiety, is characterised by disorders in serotonin, or 5-
hydroxytryptamine (5-HT), neurotransmission. It is hypothesised that immune activation may be related to 
these transmission defects, as pro-inflammatory cytokines are responsible for the lowered activity of 
presynaptic 5-HT neurons, alterations in 5-HT re-uptake from the synaptic cleft and changes in post-synaptic 
cleft 5-HT receptors (Maes et al., 1997). Similarly, 5-HT is known to modulate several leukocyte functions 
(Schiepers et al., 2005). 
Apart from its obvious diagnostic relevance, central serotonergic signalling is of great importance for 
monitoring the effects of anxiolytic and antidepressant medicines. Interestingly, expression of the SERT, 
responsible for the maintenance of serotonergic function by regulating 5-HT sequestration into cells, has 
been characterized in a range of cell types outside of the central compartment (Dürk et al., 2005; Hoirisch-
Clapauch et al., 2014; Scharinger et al., 2014). Most importantly, platelets appear to possess SERT proteins 
that are identical to those in the central nervous system (Lesch et al., 1993).  
Platelets also possess small storage and secretion granules – δ-granules – that resemble dense-core vesicles 
in neurons, in that they contain 5-HT, which is taken up and concentrated from the extracellular environment 
(Jedlitschky et al., 2012). The release of 5-HT by platelets promotes platelet functions via the serotonin 
receptor, 5-HT2A. When platelets adhere and aggregate at a site of vessel injury, 5-HT is secreted, which 
directly accelerates platelet aggregation and potentiates the response of platelets to other agonists (Hoirisch-
Clapauch et al., 2014). Human platelets have been used as a model to study 5-HT release dynamics, due to 
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these key similarities with serotonergic nerve terminals (Alvarez et al., 1999; Jedlitschky et al., 2012; 
Mumford et al., 2015). 
In the context of the immune system, secretion of the anti-inflammatory cytokine, IL-10, has been shown to 
be significantly inhibited in patients with anxiety, while increases in pro-inflammatory cytokines such as TNF-
α and IL-17 are associated with general anxiety patients (Furtado and Katzman, 2015a).  Platelets are not 
only storage sites for bioactive molecules, but also generate mediators such as thromboxane A2, and produce 
both pro-inflammatory and anti-inflammatory molecules, the most abundant of which are TNF-α, IL-8, 
platelet factor-4, MCP-1 and IL-10 (Gawaz et al., 2005; Nurden, 2011). In addition, platelets possess several 
extranuclear mechanisms that translate mRNA into proteins, and as a result can produce IL-1β and tissue 
factors (Smyth et al., 2009). 
Although laboratory assays that measure the content and release of granules were introduced over 40 years 
ago (Gresele et al., 2014), incorporation of these into clinical diagnostic practice remains inconsistent.  
However, the similarities between the platelet and neural serotonergic systems led us to hypothesise that 
platelets could be employed both in diagnosis and therapeutic monitoring in anxiety.  
To test our hypothesis, we selected two modulators of the serotonergic system with which to investigate the 
relevance of the platelet model in the context of anxiety. Firstly, citalopram was selected as reference SSRI 
(Matthäus et al., 2016). Secondly, we identified a commercially available plant extract (Trimesemine™) with 
proven anxiolytic (Bennett and Smith, 2018; Smith, 2011; Swart and Smith, 2016) and monoamine-releasing 
(Coetzee et al., 2016) properties. Our choice of this product was based on the fact that it does not seem to 
elicit  the undesired side-effects often reported for other MRAs, such as methamphetamine (Connor, 2004; 
Verrico et al., 2007). 
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 Methods & Materials 
4.2.1 Ethical considerations 
This study was approved by Stellenbosch University’s Health Research Ethics Committee (Study reference: 
SU-HSD-003976) and was carried out in accordance with the guidelines of the South African Medical Research 
Council. 
4.2.2 Subject recruitment and sample collection 
Normally healthy male and female individuals between the ages of 21 – 35 years old were recruited for 
participation in this study.  A full blood count was performed on whole blood from all participants, using 
automated analysis (Celldyne 3700CS, Abbott Diagnostics) to ensure all relevant blood parameters were 
satisfactory. In addition, a lifestyle questionnaire was completed by each participant to confirm overall health 
status, and to identify potential confounders that may affect inflammatory status and platelet function. This 
was followed by assessment of platelet parameters (international normalized ratio (INR) and activated partial 
thromboplastin time (APTT)), performed by automated analysis by commercial pathology laboratory 
(PathCare, Stellenbosch, South Africa) to determine coagulability status to reduce any confounding effects in 
the context of 5-HT release due to differences in platelet activation status.   
Only individuals with no recent illness (within 30 days) and no chronic inflammatory disorder were allowed 
into the study. All participants were also required to refrain from supplement use and alcohol or other drug 
consumption for at least one week prior to blood sampling.  
Participants completed a State-Trait Anxiety Index (STAI) questionnaire (Appendix E), a widely used measure 
of anxiety status (Julian, 2011), at the time of blood sampling (±20ml, sodium citrate anti-coagulated) for the 
platelet assay. Participants were divided into categories of state and/or trait anxiety, according to their STAI 
scores (n=6 trait anxious, n=7 non-trait anxious, n=5 state anxious and n=8 non-state anxious individuals).   
Each questionnaire (for either state or trait anxiety diagnosis) contains 20 statements that participants are 
required to rate on a 4-point scale (e.g. from “Not At All” to “Very Much So”). These statements include: “I 
am worried” and “I feel content” for the state anxiety form and “I feel nervous and restless” and “I am a 
steady person” for trait anxiety analysis. The STAI is appropriate for those who have at least a sixth-grade 
reading level. A score of 39 and above on each form indicates the presence of either state or trait anxiety, or 
both.  
4.2.3 Platelet assay 
Isolated platelets were exposed to a known activator, calcium ionophore A23187, TRI and citalopram for a 
period of 15 minutes at room temperature to assess changes in serotonergic system activity and platelet 
cytokine secretion. Vehicle (PBS) only was added to all control wells. 
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Following treatment intervention, platelets were centrifuged (400xg, 15 minutes, room temperature, no 
brake). The resulting plasma supernatant was aspirated and stored at -80°C for subsequent batch analysis of 
secreted cytokines, while the platelet samples were prepared for flow cytometry analysis of expression levels 
of selected parameters. 
4.2.3.1 Platelet isolation 
Since platelets are, by nature, highly sensitive to stimuli and naturally prone to activation, it was important 
to optimise the isolation protocol to prevent spontaneous activation due to changes in temperature, as well 
as handling and centrifugation forces. Some available protocols suggest the use of prostaglandin E1 to inhibit 
platelet activation and aggregation during isolation; however, this was not possible in the current study, since 
platelet activation in response to treatment was of interest. It was important that a low percentage of 
platelets remained inactivated before treatment intervention to effectively quantify changes. The 
optimisation process can be seen in Appendix F. 
Platelet count in whole blood was determined using automated analysis as mentioned. Platelets were then 
isolated in a series of wash and centrifugation steps. Briefly, whole blood was centrifuged (400xg, 15 minutes, 
room temperature, no brake), and the resulting plasma was gently aspirated, avoiding white blood cell 
contamination, and pooled in a new, sterile centrifuge tube. 
Plasma was centrifuged (400xg, 15 minutes, room temperature, no brake) to allow for separation into 
platelet-rich plasma (PRP) (lower two-thirds) and platelet-poor plasma (PPP) (upper one-third). The PPP layer 
was gently aspirated and stored at -80°C for later batch analysis. 
An aliquot of the remaining PRP was analysed to determine final platelet concentration. The PRP was diluted 
with PBS to achieve a final concentration of 1x108 platelets/ml. 1ml of platelet suspension was placed into 
each of four sterile 15ml centrifuge tubes. 
4.2.3.2 Treatment intervention 
4.2.3.2.1 Calcium ionophore A23187 
Platelets were treated with a final concentration of 1nmol/ml of a calcium ionophore, as per convention in 
the literature (Gobbi et al., 2003).  A working stock of 100nmol/L was made by dissolving calcium ionophore 
A23187 (Sigma-Aldrich, cat# C7522-5MG) in 99.7% dimethyl sulfoxide (DMSO) and diluting with PBS, as per 
manufacturer’s instructions. 10µl of working stock was added to the activated control group of platelets. 
4.2.3.2.2 Sceletium tortuosum extract (Trimesemine™) 
Trimesemine™ (TRI, batch number: DV SCITRI:E 591/016, Verve Dynamics Ltd, Somerset West, South Africa) 
is a commercially available extract prepared from a variety of Sceletium tortuosum that has been selectively 
propagated to achieve high mesembrine content (68.4% of total alkaloidal content). Extract characteristics 
are presented in Figure 3.1 and Table 3.1. 
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Platelets were treated with a final TRI concentration of 0.01mg/ml, as this concentration of the extract has 
been most consistently reported to have beneficial effects in other models (Bennett and Smith, 2018; 
Coetzee et al., 2016; Swart and Smith, 2016). A working stock of 1mg/ml was made by combining isolate 
powder and pre-warmed PBS. The mixture was vortexed for two minutes and sterile-filtered using a 0.22µm 
syringe filter. 10µl of working stock was added to the treatment group of platelets. 
4.2.3.2.3 Citalopram 
Platelets were treated with a final citalopram concentration of 10µmol/L per 1x106 platelets (Coetzee et al., 
2016). A working stock solution of 1mg/ml (2.45mM) was made by dissolving citalopram powder (Sigma-
Aldrich, cat# C7861) in methanol and diluting to the desired concentration with PBS, as per manufacturer’s 
instructions. 5µl of working stock per 1x106 platelets was added to the SSRI control group. 
4.2.4 Flow cytometric analysis 
Platelet pellets were resuspended in 500µl 1X BD FACS-lyse solution and incubated for 10 minutes. Platelets 
were then washed with PBS and centrifuged (800xg, 20 minutes, 4°C), the supernatant removed and 
discarded, and platelets resuspended in 500µl 0.1% saponin for 10 minutes (duration and concentration of 
both FACS-lyse and saponin treatments were optimized in a pilot study). Following the permeabilization, 
platelets were washed with PBS and centrifuged (800xg, 20 minutes, 4°C), before being finally resuspended 
in 100µl PBS with 3% FBS. 
Primary antibodies for SERT (goat anti-human) and 5-HT (rat anti-human) were added, and platelets were 
incubated in the dark for one hour at 4°C. Subsequently, platelets were washed with PBS (with 3% FBS and 
0.1% saponin) and centrifuged (400xg, 5 minutes, 4°C). Platelets were stained with secondary antibodies 
(Alexa Fluor™ 488-conjugated donkey anti-goat immunoglobulin-G (IgG) and Alexa Fluor™ 647-conjugated 
donkey anti-rat IgG), and again incubated in the dark for 1 hour at 4°C.  
Following an additional wash step, platelets were stained with conjugated antibodies for VMAT-2 (Alexa 
Fluor™ 405) (associated with 5-HT release), CD63 (BD Horizon™ PE-CF594) (marker of dense granules, which 
contain 5-HT) and CD41a (BD Horizon™ PE-Cy7) (general platelet activation marker) and incubated in the 
dark for 30 minutes at 4°C. A final wash step was performed, after which platelets were resuspended in 1% 
paraformaldehyde and assessed by flow cytometric analysis (BD FACSAriaII with BD FACSDiva v8.1 Software). 
CD41a was used as a platelet gating marker (Figure 4.1), as it is expressed by platelets and megakaryocytes 
only (Gobbi et al., 2003), and therefore data for this parameter is excluded from the results. 
For instrument setup, single stain and FMO strategies, and gating strategies for all parameters employed in 
this study, see Appendix G. 




Figure 4.1: Representative flow cytometry scatter plots and histogram illustrating platelet gating strategy 
based on CD41a expression 
4.2.5 Cytokine quantification 
Preserved platelet culture supernatants were analysed using commercial Magnetic Bead Panel assays 
(custom-designed Milliplex MAP Human Soluble Cytokine Receptor Panels, Merck Millipore) for 
concentrations of IL-1β, IL-6, IL-8, IL-10, neutrophil-activating peptide-2 (NAP2), TNF-α, MCP-1 and soluble 
CD40-ligand (sCD40L) (Appendix B). The fluorescent signals were analysed using a Bio-Rad Bio-Plex® 200 
instrument with Bio-Plex Manager v6.1 software. 
Quantification of cytokine concentrations was performed based on a standard curve, derived from linear 
dilution of the manufacturer-supplied cytokine standards. The detection limit was 0.8pg/ml for IL-1β, 
0.9pg/ml for IL-6, 0.4pg/ml for IL-8, 1.1pg/ml for IL-10, 11.2pg/ml for NAP2, 0.7pg/ml for TNF-α, 1.6pg/ml for 
MCP-1, and 5.1pg/ml for sCD40L.  Levels of secretion for IL-1β and IL-6 were extremely low in most cases. 
Thus, this data was excluded from statistical analysis. 
4.2.6 Statistical analysis 
Results in graphs are presented as means, and standard error of the means (SEMs). Normality of data 
distribution was assessed, followed by non-parametric 2-way ANOVA and LSD post hoc tests. In cases where 
Levene’s Test for Homogeneity of Variances rejected the null hypothesis, the Games-Howell post hoc test 
was used (Statistica v13.2). Results in tables are presented as means ± standard deviations. 
  




Basic participant characteristics and clotting profiles are presented in Table 4.1. All parameters were within 
the expected normal ranges for all individuals (n=13, nine males and four females).  
Table 4.1: Participant basic characteristics at blood sampling, as well as basic haematology profiles 
 Expected normal range Mean ± standard deviation (n=13) 
Age (years)  25 ± 2.75 
Height (cm)  173.33 ± 8.55 
Weight (kg)  74.16 ± 10.87 
Body mass index 18.5 – 24.9 24.81 ± 2.15 




0.9 – 1.3 
25.4 – 38.4 
 
1.07 ± 0.08 
31.32 ± 2.80 
Baseline whole blood parameters: 
Leukocyte count (109 cells/L) 
Red blood cell count (1012 cells/L) 
Platelet count (109 cells/L) 
Haematocrit (%) 
 
4.00 – 10.25 
3.70 – 6.18 
145 – 400 
36 – 54 
 
6.07 ± 1.40 
4.83 ± 0.36 
239.38 ± 58.69 
41.16 ± 4.14 
 
According to anxiety profile of the study population, state and trait anxiety scores were correlated in this 
population as expected (p<0.001) (Figure 4.2A). Six individuals fulfilled clinical criteria for trait anxiety and 
five for state anxiety (including four exhibiting both trait and state anxiety) (Figure 4.2B).   
 
Figure 4.2: (A) State-trait anxiety correlation and (B) quantification of participants with/without either state 
or trait anxiety, as determined by STAI scoring. 
r=0.691 
p<0.001 
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For all individuals exhibiting anxiety, either state or trait anxiety, platelet intracellular 5-HT levels were 
significantly lower when compared to no-anxiety controls (Figure 4.3A and B), with no additional effect 
apparent for either treatment.  In no-anxiety controls, both TRI and citalopram decreased 5-HT levels 
significantly.  
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Figure 4.3: (A) Platelet intracellular 5-HT content in samples obtained from individuals with/without state 
anxiety and (B) with/without trait anxiety. (C-F) Platelet parameters indicative of 5-HT storage and/or release 
in individuals with/without state or trait anxiety respectively: membrane VMAT-2 and CD63. (G and H) Platelet 
membrane-bound SERT, indicative of 5-HT re-uptake potential, in individuals with/without state or trait 
anxiety. *p<0.00001 
For VMAT-2, neither state nor trait anxiety seemed to affect expression levels (Figure 4.3C and D). However, 
TRI significantly reduced VMAT-2 expression in individuals exhibiting trait anxiety, when compared to other 
conditions. In contrast, both state and trait anxiety significantly decreased CD63 expression on platelets 
(Figure 4.3E and F; main effect of trait anxiety, p<0.00001). This parameter did not seem to be affected by 
either treatment.  
In terms of 5-HT re-uptake, SERT expression showed a weak tendency to be lower for trait anxiety (ANOVA 
main effect of trait anxiety, p=0.09) but not state anxiety when compared to controls (Figure 4.3G and H). In 
individuals with state anxiety, citalopram showed a tendency for increasing SERT expression. In individuals 
with no state anxiety, SERT expression was higher after treatment with TRI when compared to treatment 
with citalopram (Figure 4.3G). In line with this, the decrease in SERT expression as result of trait anxiety only 
reached significance in the TRI treatment condition. 
Table 4.2 shows the concentrations (pg/ml) of each cytokine measured for this study. Due to large inter-
subject variation, each subject was standardised to their own untreated control, with cytokine 
concentrations expressed as a percentage of their control conditions (Figure 4.5 and Figure 4.6). Due to the 
variability between individuals, we also decided to not exclude values on the lower detectable limit, as these 
gave valuable insight into the effects of anxiety on subject responsiveness to treatment interventions. 
Table 4.2: Platelet supernatant cytokine concentrations following treatment intervention 
 Cytokine concentration (pg/ml) (mean ± standard deviation, n=13) 
 TNF-α IL-8 MCP-1 IL-10 sCD40L NAP2 
Control 11.07±5.65 5.20±5.91 185.20±43.57 6.76±9.09 115.77±42.59 
637154.28± 
197121.28 
Calcium ionophore 11.79±5.73 5.12±5.46 186.31±38.13 6.85±9.08 134.32±58.66 
693961.85± 
168077.96 
Trimesemine 9.50±6.16 4.85±6.10 168.05±50.69 6.05±9.21 108.16±47.52 
596910.98± 
150128.42 
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The variability between participants was further exacerbated by the presence or absence of state and/or trait 
anxiety. An example of this can be seen when looking at the changes in absolute concentrations of MCP-1 
(Figure 4.4A-D) in the supernatant, following treatment intervention. This interpersonal variability due to 
anxiety type further supported the expression of each cytokine concentration as a percentage of its control 
conditions. 
 
Figure 4.4: Absolute concentration of MCP-1 in platelet supernatant following treatment intervention, in (A) 
state anxious individuals, (B) trait anxious individuals, (C) non-state anxious individuals and (D) non-trait 
anxious individuals 
In terms of pro-inflammatory cytokines commonly assessed in the neuroimmunology literature – TNF-a, IL-8 
and MCP-1 – TRI generally seemed to have a suppressive effect on platelet pro-inflammatory cytokine release 
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compared to citalopram (Figure 4.5G and H) in the state anxiety group. In contrast, citalopram did not appear 
to have any effect on these parameters. 
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Figure 4.5: Pro-inflammatory cytokine secretion assessed in supernatants of platelet primary cultures treated 
with either a calcium ionophore, TRI or citalopram, in both (A,C,E) state and (B,D,F) trait anxiety. Anti-
inflammatory cytokine secretion assessed in supernatants of platelet primary cultures treated with either a 
calcium ionophore, TRI or citalopram, in both (G) and (H) trait anxiety 
In this model, secretion levels of platelet-specific markers of activation – sCD40L and NAP2 – were in line 
with decreased serotonergic system-specific activation (CD63) as result of trait anxiety but did not appear 
similarly sensitive to reflect anti-inflammatory effects of TRI (Figure 4.6A-D). 
 
 
Figure 4.6: Platelet-specific markers of inflammatory activation assessed in supernatants of platelet primary 








As agreement with the literature on neuronal SERT (Matthäus et al., 2016; White et al., 2005), platelet SERT 
expression was down-regulated in the state anxiety model, in response to citalopram treatment. This 
validates platelets as a suitable model of the central serotonergic system in this setting. In addition, results 
reported here in platelets are in line with those reported after  similar studies performed on 5-HT-secreting 
neural cells (Coetzee et al., 2016; Jaiswal et al., 2015). Furthermore, in the absence of anxiety, changes in 
intraplatelet 5-HT were evident between the control and treatment groups, further supporting the use of 
this model to investigate 5-HT release using platelets from normally healthy individuals. 
In the setting of anxiety, this study has highlighted key differences not only between anxious and non-anxious 
individuals, but also between anxiety types, in terms of serotonergic system parameters as well as 
inflammatory responses. Since the physiological response to anxiety involves the release of 5-HT from 
serotonergic neurons and platelet stores (Graeff et al., 1996), it is understandable that intraplatelet levels of 
5-HT and VMAT-2 are already low in the control groups of both state- and trait-anxious individuals (Figure 
4.3A and B). These findings are supported by previous studies that showed low levels of 5-HT in the ventral 
striatum of rats with anxiety (Schwarting et al., 1998; Sommer et al., 2001).  
However, the differences between anxious and non-anxious individuals in terms of intraplatelet 5-HT are 
staggering, with platelets from non-anxious individuals containing ±15 times more 5-HT than anxious (both 
state and trait) individuals under basal conditions. This corresponds with platelet CD63 expression (in trait 
anxiety). CD63 is indicative of the presence of δ-granules, the storage site for platelet 5-HT. The fact that the 
effect of anxiety on CD63 is only evident in the trait group, suggests that while 5-HT levels cannot distinguish 
between acute and chronic anxiety states, CD63 as marker is less sensitive to acute anxiety.  
The implication here is that while 5-HT release is a relatively acute process, the downregulation of dense 
granule content in platelets occur more gradually. Nevertheless, in terms of the applicability of the platelet 
model, the significantly lower intraplatelet 5-HT content and CD63 expression are indicative of depletion of 
this neurotransmitter in anxiety states, albeit at different rates, to the point where the effects of any 
treatment cannot be observed. This limitation of the model is probably a result of the fact that platelets 
cannot synthesise 5-HT (Hoirisch-Clapauch et al., 2014). An option to investigate may be to supplement the 
culture media with 5-HT to replenish intraplatelet 5-HT stores – although this may interfere with assessments 
of SSRI function, it may be beneficial for the study of 5-HT release and the effect of pharmaceuticals on this 
process. 
Somewhat similar to the CD63 data, the study of membrane VMAT-2 expression also elucidated significant 
differences between state and trait anxiety. While VMAT-2 levels appeared unaffected by state anxiety, trait 
anxiety was associated with a decrease in membrane VMAT-2 expression in response to calcium ionophore 
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A23187 activation, suggesting an imbalance between 5-HT release and reuptake in individuals with trait 
anxiety (Reimold et al., 2008; Schwarting et al., 1998).  Interestingly, after TRI treatment VMAT-2 expression 
decreased almost 1.5-fold compared to the non-treated group upon activation, sensitively reflecting the MRA 
function of TRI.  
Together, these findings provide important information on the use of the platelet model for the study of 5-
HT secretion. Firstly, the platelet model may be an accurate tool for differential diagnosis and monitoring of 
anxiety once a reference range for platelet levels of the parameter panel has been established. Secondly, 
platelets from non-anxious donors could be used in drug development studies, to provide sufficient capacity 
to reflect therapeutic effects in platelet 5-HT level. 
In further support of our choice of MRA substance, Sceletium tortuosum has, until recently, been regarded 
primarily as an SSRI (Gericke and Viljoen, 2008; Terburg et al., 2013). However, this concept was challenged 
by findings from a recent study on TRI, which found that the high-mesembrine Sceletium extract had a greater 
up-regulatory effect on VMAT-2 expression in comparison to citalopram treatment (Coetzee et al., 2016). 
Since VMAT-2 is known to facilitate monoamine storage as well as release (Hoirisch-Clapauch et al., 2014), 
these findings suggested that TRI may act more so as an MRA, and possesses SSRI activity only as a secondary 
effect. Current data confirms this interpretation, specifically in the non-trait anxiety group, where VMAT-2 
expression after TRI exposure was significantly lower than in the calcium ionophore A23187-activated group 
and tended to be lower than in platelets exposed to citalopram. 
Furthermore, when considering  platelet contribution to the inflammatory response characterising anxiety 
states, it was apparent that TRI exerts the most favourable effects in terms of limiting pro-inflammatory 
cytokine production, especially when compared to citalopram, which has been found to increase levels of IL-
1β and TNF-α (Furtado and Katzman, 2015b; Munzer et al., 2013). This is in line with our previous work 
(Bennett et al., manuscript under review), where human astrocyte pro-inflammatory cytokine production 
was significantly limited by both 0.01mg/ml and 1mg/ml TRI doses in the setting of acute endotoxin 
stimulation (E.coli LPS). These findings indicate that the platelet model is sensitive enough to illustrate 
inflammatory side-effects that may be associated with certain anxiolytic and anti-depressant treatments. 
In addition, TRI has also shown to increase secretion of IL-10 in both the current platelet model and in human 
astrocytes. Since both anxiety and depression have been shown to stimulate the secretion of pro-
inflammatory cytokines (Anisman and Merali, 2002; Kiecolt-Glaser et al., 2015; Miller et al., 2009; Schiepers 
et al., 2005), this inflammation-limiting effect linked to TRI exposure is an added benefit, which may, at least 
in part, contribute to its better safety profile in comparison to other MRAs.  
Finally, investigation of platelet-specific inflammatory activation, in terms of sCD40L and NAP2 expression, 
did not reflect differences between control or anxiety states. Similarly, neither sCD40L, nor NAP2 was 
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affected by either treatment employed. Thus, in the context of anxiety-related inflammation, these are 
probably less useful markers.  
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Chapter 5 – Final Conclusions and Directions for Future Research 
Improving lifestyle stress exposure and making responsible choices about one’s health and wellbeing are vital 
in elevating overall health status. Managing continual stress exposure requires the ability to recognize 
stressors and respond constructively, limiting behaviours that exacerbate the strain on physiological stress-
response mechanisms. However, it is not always easy to avoid chronic stress, especially in the fast-paced, 
success-driven world today. Therefore, research into potential therapeutic interventions for consequences 
of the modern-day lifestyle is of great importance. 
From current data it is clear that the Sceletium tortuosum extracts tested have potential in the preventative 
medicine niche, specifically in terms of limiting inflammation and/or oxidative stress to achieve a rate-limiting 
effect on chronic inflammatory disease development. However, the effects of Sceletium extracts and/or their 
isolated pure alkaloids on endocrine-immune interaction need to be further elucidated, to enable 
optimisation of the use of this indigenous product in the setting of chronic lifestyle diseases, such as type II 
and type III diabetes.  
Distinct, bidirectional links exist between enduring psychological stress, chronic activation of the 
inflammatory response, and the development of non-communicable diseases. The severity of physiological 
maladaptations in response to recurring lifestyle stress or in response to traumatic events are clear in our 
platelet assay results, where significant differences are evident in acute and chronic anxiety, in terms of 
response to commercial treatments. This is confirmed by Ross et al. (2017), whose extensive review on 
chronic stress in anxiety and depression concluded that patients with comorbid depression and anxiety are 
less likely to respond effectively, if at all, to currently approved medications. 
Centrally, anxiety and depression are both a cause and result of 5-HT depletion in serotonergic neurons, and 
decreased receptor and reuptake transporter density. From the platelet model, we could confirm that 5-HT 
hyperresponsiveness is a hallmark maladaptation in the setting of repeated stress-response stimulation, but 
not in acute stimulation, with low intraplatelet 5-HT and increased platelet activation in trait anxiety. 
The significant changes in platelet 5-HT stores, release and reuptake dynamics, and major cytokine 
production indicate that this model is useful in the study of 5-HT-mediated inflammation, specifically in the 
context of anxiety. Our platelet model has also indicated how differing degrees of mental health contribute 
to challenges in diagnosis and timely treatment. 5-HT reuptake and release assays would shed more light on 
this, where intraplatelet stores can be replenished before treatment exposure, to observe changes in 
response to treatments in anxious individuals. 
Assessment of changes in expression of platelet SERT and VMAT-2 following treatment exposure, performed 
at a series of time points, would give greater insight into the mechanisms of action behind 5-HT release 
dynamics. For example, since platelets cannot synthesise 5-HT, continual 5-HT release is facilitated by 
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monoamine reuptake via SERT. Thus, if prolonged exposure to the mild and intended SSRI effects of TRI and 
citalopram, respectively, may result in VMAT-2 downregulation over time, but this would not be immediately 
evident. 
Further elucidation of Sceletium tortuosum’s effects on cytokine secretion may be achieved through 
investigation of the in vivo effects of Sceletium supplementation on immune cells, which may provide 
information regarding biological factors that may act in synergism or antagonism with this natural product. 
This setting may also lend itself to examination of relative pro- and anti-inflammatory cytokine peaks and 
half-lives, through the study of multiple time points following treatment intervention.  
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Abstract 
Ethnopharmacological relevance: Sceletium tortuosum, among other Sceletium species, was traditionally used 
by the Khoisan people of Southern Africa for relief of pain-related ailments. However, the commercial 
availability of this supplement has greatly expanded due to anecdotal claims of its mood-elevating and 
anxiolytic properties. Unrelated research has elucidated a significant link between cytokines and the mediation 
of depression. Therefore, the effect of Sceletium supplementation on immune cell functionality is of interest, 
since the efficacy of potential depression treatments could, at least in part, rely on downregulation of pro-
inflammatory signalling. 
Aim of the study: The current study evaluated the immunomodulatory effects of a Sceletium extract, both 
basally and in the context of acute endotoxin stimulation. 
Materials and Methods: Primary human monocytes were supplemented with either a 0.01mg/ml or 1mg/ml 
Sceletium extract dose, with or without E. coli LPS stimulation in vitro, for 24 hours. Mitochondrial viability, as 
an indirect measure of cytotoxicity, and cytokine release in response to the treatment intervention were 
assessed. 
Results: Sceletium extract treatment was associated with increased mitochondrial viability, as well as up-
regulated IL-10 release under basal conditions. LPS exposure significantly decreased mitochondrial viability, 
but this was prevented completely under Sceletium-treated conditions. The acute inflammatory response to 
LPS stimulation was not negatively affected. Sceletium treatment conferred most significant effects at a dose 
of 0.01mg/ml. 
Conclusions: Sceletium exerts significant cytoprotective effects in the setting of endotoxin stimulation. 
Cytokine assessment indicated that Sceletium possesses mild anti-inflammatory properties but does not 
hinder the mounting of an adequate immune response to acute immune challenge. These findings indicate 
that Sceletium may be beneficial for the attenuation of cytokine-induced depression, as well as in systemic 
low-grade inflammation. 
Key words: Sceletium tortuosum, alternative medicine, anti-inflammatory, cytokine, monocyte, LPS 
  





ANOVA Analysis of Variance 
DPBS Dulbecco’s Phosphate Buffered Saline 
ELISA Enzyme-Linked Immunosorbent Assay 
FBS Foetal Bovine Serum 
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MCP-1 Monocyte Chemotactic Protein-1  
PBMC(s) Peripheral Blood Mononuclear Cell(s) 
RPMI media Roswell Park Memorial Institute media 
SEMs Standard Error of the Mean(s) 





According to the latest World Health Organisation statistics, an estimated 4% of the global population is 
afflicted with depression. With this number ever increasing, the search for new and effective ways to address 
the symptoms and modulate both central and peripheral maladaptations to stress-related conditions, remains 
one of the most important focus areas in research. Although medications are currently available for the 
management of depressive conditions, less than half (and in many developing countries, less than 10%) of the 
afflicted population receive such treatments.  
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In South Africa, as in many developing countries, general practitioners are largely outnumbered by traditional 
healers. Therefore, it is not surprising that a tendency exists for patients to turn to traditional plant and herbal 
remedies for the treatment of ailments and disorders (Morris, 2001). Thus, the effectiveness of natural 
medicines with potential anti-stress capacity has been the focus of several research groups for some time, and 
one candidate which has shown great potential in this setting is Sceletium tortuosum.  
Traditionally, Sceletium tortuosum, among other Sceletium species, was used by the Khoisan people of 
Southern Africa for the relief of toothache and stomach pain (Harvey et al., 2011; Loria et al., 2014; Murbach 
et al., 2014; Patnala and Kanfer, 2013), and the commercial availability of this herbal supplement has increased 
considerably as a result of anecdotal claims of its mood-elevating and anxiolytic properties (Shikanga et al., 
2012). However, this commercial expansion is associated with increasing concerns relating to the quality of, 
and consistency across available Sceletium products. 
It is important to note that the alkaloidal composition of a supplement is a key determinant of both its 
beneficial and adverse effects (Nell et al., 2013). This being said, the alkaloidal composition of raw Sceletium 
is complex, and further complicated by post-harvesting interventions which have shown to alter plant 
composition across the majority of herbal supplements (Smith, 2011). Sceletium tortuosum is widely available 
as an herbal extract for daily supplementation, but little information is available regarding the phytochemical 
contents, which is necessary for quality control.  
In terms of its effectiveness in the context of stress, Sceletium extract has been shown to have both 
effectiveness as monoamine releasing agent and selective serotonin reuptake inhibitor (Coetzee et al., 2016), 
and to limit glucocorticoid production via inhibition of specific adrenal p450 enzymes (Swart and Smith, 2016). 
In addition, rats subjected to experimental restraint stress after being supplemented with crude Sceletium 
tortuosum extract, did exhibit less anxiety behaviour. However, they also presented with increased circulating 
levels of the pro-inflammatory cytokine, interleukin-1-beta (IL-1β) (Smith, 2011). Although the unrefined 
nature of the product used may have been responsible for this result, this potentially undesired effect of 
Sceletium supplementation may have far-reaching implications for consumers. 
According to the Cytokine Hypothesis of Depression, a significant link exists between cytokines and the 
mediation of depression (Anisman and Merali, 2002; Maes et al., 1995; Schiepers et al., 2005). It has 
furthermore been suggested that cytokine inhibitors, aside from their anti-inflammatory effects, may be 
capable of offsetting depressive symptoms that accompany chronic inflammation (Dantzer, 2004; Yirmiya, 
1996). Therefore, the effect of Sceletium supplementation on immune cell functionality is an important area 
of study, as the efficacy of potential treatments for depression may rely on their ability to down-regulate pro-
inflammatory cytokine production.  
In the current study, it was hypothesised that the anti-depressive and anxiolytic properties claimed for 
Sceletium are exerted via immunomodulation - specifically anti-inflammatory effects. Our aims were therefore 
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firstly to determine the effects of a commercially available high-mesembrine Sceletium extract, 
Trimesemine™, on primary human monocyte viability, both basally and in the presence of an acute pro-
inflammatory stimulus (Escherichia coli lipopolysaccharide, LPS), the latter to simulate severe acute 
inflammatory challenge. The second aim of this study was to investigate the functional capacity of these 
immune cells, following treatment with Trimesemine™.  
Materials and Methods 
Ethical considerations 
Human primary isolated monocytes were employed in this study. Ethical clearance for blood collection was 
obtained from Stellenbosch University Subcommittee C Human Research Ethics Committee (Study reference 
X15/05/013). Monocytes were isolated from peripheral blood buffy coats obtained from healthy donors 
between the ages of 18 and 25 years old, which were provided by Western Province Blood Transfusion Services 
(South Africa). 
Cell culture 
Preparation of intervention media  
A lyophilised extract (Trimesemine™ (Tri)), prepared from a proprietary hybrid (DV17) of S. tortuosum (L.) N.E. 
Br. and S. expansum (L.) L. Bolus (family Aizoaceae) using a proprietary method, was obtained from Botanical 
Resource Holdings Pty (Ltd) affiliate Verve Dynamics (Somerset West, South Africa) (Lot #BTRMA:001/024, 
manufacturing reference# DV SCIET:E 028/024 (24123) (refer to Swart and Smith, 2016 for the certificate of 
analysis and quality control data).  
We have previously shown a 0.01mg/ml solution to be most beneficial in an in vitro setting (Coetzee et al., 
2016), thus a 0.01mg/ml Trimesemine™ solution was prepared in serum-free Roswell Park Memorial Institute 
(RPMI) media. The mixture was vortexed for two minutes and filtered through a 0.22µm syringe filter.  As 
representative of a supra-physiological dose, a 1mg/ml solution was also included. For the inflammatory 
challenge, a 1mg/ml LPS (Sigma Aldrich, L4391) stock solution was made in Hank’s Balanced Salt Solution 
(HBSS), as per manufacturer’s instructions. 
Cell propagation 
Human peripheral blood mononuclear cells (PBMCs) were separated from the buffy coat using a Histopaque 
(Sigma Aldrich, 10771) density gradient. Following centrifugation, the PBMCs were collected, and centrifuged 
over PercollPLUS (Sigma Aldrich, E0414) density gradients. The resulting monocyte-rich layers were then 
collected and re-suspended in complete RPMI (RPMI 1640 media containing 10% Foetal Bovine Serum (FBS), 
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1% Penicillin/streptomycin, 1% GlutaMAX (Gibco® by Life Technologies™, 35050-038) and β-mercaptoethanol 
(Sigma Aldrich, M3148)) (Menck et al., 2014). 
The purified monocytes were seeded into a 48-well culture plate at a density of 1 x 105 cells/well in complete 
RPMI. Cells were incubated at 37°C, 5% CO2 and the medium was refreshed every two days until 90% 
confluence was reached. It was observed that the cultured primary monocytes went through cycles of 
adherence and non-adherence to the culture plate surface, and thus media refreshment involved aspiration 
of the supernatant and centrifugation (400 x g, 10 minutes, without brake, room temperature), following 
which the supernatant was discarded, and the cell pellets re-suspended in fresh complete RPMI and returned 
to their respective wells. 
Trimesemine™ treatment intervention 
At desired confluence levels, supernatant was aspirated and placed in microfuge vials, and the wells washed 
once with DPBS. The DPBS was aspirated and added to the vials containing the media from each well, to avoid 
loss of non-adherent monocytes through the washing process. The microfuge vials were centrifuged as 
previously described, the supernatant removed, and the cell pellets re-suspended in either 0.01mg/ml or 
1mg/ml Trimesemine™-containing media, or serum-free media (control groups), and returned to the 
respective wells. 
After 30 minutes, the following were added to each well: (i) LPS stock solution to LPS-control and LPS-
stimulated wells to achieve a final LPS concentration of 50ng/ml (Ross et al., 2013), and (ii) LPS vehicle (HBSS) 
to the unstimulated wells. The cells were then incubated for a further 23.5 hours under standard tissue culture 
conditions. All experiments were performed at least three times, in duplicate. 
Viability testing 
The XTT (2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide) assay is a commonly used 
test method to indirectly measure cell viability, through assessment of mitochondrial viability (Wang et al., 
2011). Following the 23.5-hour incubation period, the supernatant was removed from each well and 
centrifuged. The resulting supernatant was aliquoted and stored at −80°C for subsequent batch analysis, while 
the remaining cell pellet was re-suspended in XTT solution (1mg/ml) and returned to their respective wells for 
incubation (4 hours, 37°C). 
Following incubation, optical densities were determined at 490nm, using a Universal Microplate Reader 
(EL800, Bio-Tek Instruments, Inc.) and analysed using KCjunior for Windows Data Reduction Software (v1.41.3). 
Cytokine measurement  
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Cell-free culture supernatant was analysed using a commercial Magnetic Bead Panel assay (custom-designed 
6-plex Milliplex MAP Human Soluble Cytokine Receptor Panel, Merck Millipore), as well as an ELISA Kit 
(BioLegend, 438807), for concentrations of IL-1β, IL-4, IL-6, IL-10, tumour necrosis factor-alpha (TNF-α) and 
monocyte chemotactic protein-1 (MCP-1), respectively. Cytokine responses were expressed as absolute 
concentrations in cell culture supernatant. 
Quantification of cytokine concentrations was performed based on a standard curve, derived from linear 
dilution of the manufacturer-supplied cytokine standards. The lower detection limit was 0.8pg/ml for IL-1β, 
4.5pg/ml for IL-4, 0.9pg/ml for IL-6, 1.1pg/ml for IL-10, 0.7pg/ml for TNF-α and 1.6pg/ml for MCP-1. 
To understand cytokine secretion in the context of relative viability, an index was calculated using the formula 
below, to correct the level of cytokines produced for the percentage of viable mitochondria: 
Corrected cytokine secretion index = log10(cytokine concentration/mitochondrial viability (% control) × 100) 
Statistical Analysis 
Results are presented as averages and standard error of the means (SEMs). Effects of Trimesemine™ and LPS 
stimulation were statistically analysed by assessing normality of data distribution, followed by a non-
parametric 2-way ANOVA and LSD post hoc tests. If Levene’s test for homogeneity of variances rejected the 
null hypothesis, the Games-Howell test was used as a post hoc test instead (Statistica v.12, StatSoft). 
Differences were considered significant at p<0.05. 
Results 
The major findings of this study were that Trimesemine™ supplementation significantly increased monocyte 
viability in the setting of acute immune challenge. In addition, it was observed that Trimesemine™ exerted 
anti-inflammatory effects at basal level, through up-regulation of monocyte IL-10 secretion but did not 
interfere with the cells’ ability to mount an adequate inflammatory response following LPS exposure. 
At both concentrations, Trimesemine™ treatment was not associated with cytotoxic effects on monocytes, as 
assessed by XTT (Figure 1). In the absence of LPS, a significant increase in mitochondrial viability was observed 
in the low dose Trimesemine™ treated condition only, indicating a clear dose-response effect of 
Trimesemine™ supplementation. LPS exerted significant cytotoxic effects on the primary human monocytes 
at a concentration of 50ng/ml, resulting in a 66% decrease in XTT viability, which was prevented completely 
by both Trimesemine™ doses. 




Figure 1: Dose-dependent primary monocyte mitochondrial viability after exposure to Trimesemine™ 
with/without LPS for 24 hours. * = p<0.05 (compared to Ctrl); *** = p<0.0001 (compared to Ctrl); ### = 
p<0.000001 (compared to Ctrl (+ LPS)) 
In terms of pro-inflammatory cytokine secretion, monocytes produced detectable absolute levels of IL-1β, IL-
6 and TNF-α under basal conditions - a response significantly upregulated for all three cytokines in response 
to LPS stimulation (Figure 2A-C). Basal secretion levels for MCP-1 was relatively higher than for the other 
cytokines – which is consistent with the literature (Muenster et al., 2015; Ross et al., 2013; Weldon et al., 
2007) – with a dampening effect evident for the high dose Trimesemine™ treatment. Similar to the other 
cytokines, a significant elevation was seen in response to LPS treatment (Figure 2D). 




Figure 2: Effect of Trimesemine™ treatment with/without LPS stimulation on pro-inflammatory (A, B, C and 
D) and anti-inflammatory (basal only on different axes for clarity, E1 and all conditions, E2) cytokine 
production by primary human monocytes, as compared to the control. Φ = Main effect of LPS treatment, 
p<0.01; * = p<0.05 (compared to Ctrl); ** = p<0.005 (compared to Ctrl); **** = p<0.000001 (compared to 
Ctrl); # = p<0.001 (compared to Ctrl (+ LPS)); ψ = p<0.05 
In comparison to the LPS-stimulated condition, and when considering that the average basal levels for 
cytokines are very close to the lower detection limits for these assays, monocyte cytokine secretion in 
response to Trimesemine™ does not give any indication that this extract exerts pro-inflammatory effects under 
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basal conditions. This interpretation is further supported by the corrected cytokine indices for the pro-
inflammatory cytokines (Figure 3A-E; please note that the Y-axes have a log scale). 
Figure 3: The monocyte cytokine-viability index per treatment group on a logarithmic scale (base-10). Φ = 
Main effect of LPS treatment, p<0.01; * = p<0.05 (compared to Ctrl); ** = p<0.005 (compared to Ctrl)); # = 
p<0.001 (compared to Ctrl (+ LPS)); ## = p<0.005 (compared to Ctrl (+ LPS)) 
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Under LPS-challenged conditions, neither dose of Trimesemine™ seemed to inhibit absolute pro-inflammatory 
cytokine concentrations, except for a lower IL-6 response after high dose treatment.  However, when 
correcting cytokine levels according to relative mitochondrial viability, a consistent dose effect emerges, with 
Trimesemine™ treatment lowering the pro-inflammatory response to LPS challenge (Figure 3A-D). However, 
although dampened, the response mounted was still significant relative to basal conditions.  
Turning to the anti-inflammatory cytokines, IL-4 secretion was below the lowest detectable limit across all 
treatment groups (data not shown). In contrast, basal IL-10 (Figure 3E1) secretion was significantly increased 
by Trimesemine™ supplementation in a dose-dependent manner, with statistical significance reached after 
treatment with the higher dose. In contrast to basal levels, under LPS treated conditions, Trimesemine™ 
treatment was associated with lower IL-10 secretion, most probably as a result of the lower pro-inflammatory 
response to LPS in the treated groups. 
Discussion 
The current study presents a novel approach to the elucidation of Sceletium’s potential immunomodulatory 
properties, firstly through the simultaneous investigation of pro- and anti-inflammatory cytokine production, 
which to our knowledge has not been performed in other immune cell dose-response ethnopharmacological 
studies in the context of Sceletium. This was motivated by the fact that individual cytokines have overlapping 
regulatory actions which may be synergistic, additive or antagonistic (Balkwill and Burke, 1989; Cavaillon, 
1994), emphasising the importance of studying a broad range of cytokines. Secondly, this study elucidated the 
effects of a mesembrine-rich commercial Sceletium product on leukocyte basal and acute stimulus-induced 
inflammatory cytokine production, which to our knowledge has not been previously reported in the literature.  
The rationale for the use of monocytes as a model was that they are a major source of cytokines, and are 
characterised by maximal cytokine synthesis within hours of activation (Beutler, 2004; Cavaillon, 1994). It has 
been observed that these cells are capable of production and release of an impressive panel of cytokines, 
including, but not limited to, IL-1α, IL-β, IL-6, IL-8, IL-12, TNF-α, interferon-gamma (IFN-γ) and MCP-1 
(Cavaillon, 1994). 
The fact that monocyte mitochondrial viability decreased significantly after LPS challenge validates the 
sensitivity of the model to reflect changes in cell viability. Current data indicates that Trimesemine™ did not 
exert cytotoxic effects at either dosage under basal conditions.  
Furthermore, and most importantly contributing to the literature evidence for another major physiological 
effect of Sceletium, Trimesemine™ treatment conferred cytoprotective effects onto immune cells in the 
presence of acute endotoxin stimulation, thus maintaining XTT viability at control levels. The significance of 
this result is considerable. Firstly, LPS is known to activate immune cells such as monocytes  primarily by 
binding to Toll-like receptor 4, resulting in activation of intracellular kinases and transcription factors, such as 
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mitogen-activated protein (MAP) kinases and NF-κB, respectively (Lu et al., 2010). The resultant immune 
response is characterised by release of pro-inflammatory cytokines, nitric oxide and eicosanoids, all of which 
upregulates the immune response required for removal of the pathogen. However, it is known that normal 
inflammatory processes results in significant secondary damage to host cells themselves (Smith et al., 2008), 
as indeed evidenced by the significant drop in XTT viability in the LPS-control cells.  
Current data thus suggests that Sceletium may protect host immune cells from this secondary damage, thereby 
effectively enabling the immune system to more efficiently rid the host of the pathogen, with less severe 
clinical symptoms. Secondly, the fact that the immune cells are protected from the nitric oxide (a free radical) 
that they secrete in response to LPS, also have implications in the context of sterile inflammation. It is known 
that many chronic diseases are characterised by increased levels of oxidative stress and low-grade 
inflammation. Thus, the potential for Sceletium to also have antioxidant capacity in this context, in 
combination with its illustrated anti-stress and anti-anxiety effects (Smith, 2011; Terburg et al., 2013), suggests 
that this plant medicine may be the magic bullet with which to counter the effects of many modern lifestyle-
associated diseases. In further support of this notion, the striking cytoprotective effect of Sceletium was 
associated with significant desired modulatory effects in the context of inflammatory signalling.  
The fact that Trimesemine™ up-regulated basal IL-10 secretion, may indicate that this Sceletium extract 
possesses mild anti-inflammatory potential. Importantly, despite this effect, the monocytes could mount an 
adequate response to LPS stimulation in the presence of Trimesemine™, with a significant up-regulation of IL-
10 secretion in response to increased IL-6 production induced by LPS. This result is positive, as it provides 
evidence to suggest that although a mild modulation by Trimesemine™ under basal conditions may have 
significance in terms of longer term clinical outcome, its consumption will not hinder the immune response to 
an acute, pathogenic challenge. 
Interestingly, when considering absolute cytokine levels, high-dose Trimesemine™ appeared to result in a 
smaller IL-6 response to LPS, which indirectly resulted also in decreased monocyte IL-10 secretion. However, 
when corrected for mitochondrial viability, this dose-effect was not maintained. This suggests that even small 
(statistically insignificant) differences in mitochondrial viability may affect the cell’s functional capacity to 
produce and/or secrete pro-inflammatory cytokines significantly. The more limited inflammatory cytokine 
response to LPS in the presence of higher dose Trimesemine™ may be interpreted in two ways. Firstly, the 
higher dose may limit the undesired symptomatic effects of the inflammatory hyper-response to LPS, which is 
a favourable clinical outcome. Secondly however, it is possible that this reduced response may be the result 
of detrimental immunosuppression. However, this seems unlikely, since the cytokine response was still 
significantly increased in response to LPS when compared to control. Rather, since the high dose employed in 
the current study represents a supraphysiological dose at least 100-fold higher than suggested daily 
consumption, this data suggest low risk of overdose, at least in terms of immune capacity and resistance to 
pathogenic infection.  
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In terms of the low levels of IL-4 in the current study, a relatively short serum half-life  of approximately 20 
minutes was reported for IL-4 following intravenous administration (Conlon et al., 1990). This could account 
for the undetectable levels of IL-4 across all treatment groups in the current study, where cytokine 
assessments were carried out only after a 24-hour intervention. This finding necessitates a need for more time 
points during the treatment period, to more comprehensively elucidate the secretion peaks for each relevant 
cytokine. This also indicates that IL-10 serves as a more viable marker for anti-inflammatory profile, as it 
provides more conclusive results when assessment of fewer time points apply.  
To place current results in context with other physiological effects reported for Sceletium, exposure to 
psychological stress has been implicated in defects in production of pro-inflammatory cytokines (Anisman and 
Merali, 2002; Maes et al., 1995; Schiepers et al., 2005). It is hypothesised that immune activation may be 
related to depression-related neurotransmission defects, as pro-inflammatory cytokines themselves have 
been implicated in alterations in norepinephrine and serotonin/5-hydroxytryptamine (5-HT) turnover in brain 
regions known to be involved in depression, including the amygdala, hypothalamus, hippocampus and 
prefrontal cortex (Anderson and Maes, 2015; Dantzer, 2004; Godbout et al., 2005; Poon et al., 2015). 
Cytokines are responsible for the lowered activity of presynaptic 5-HT neurons, also due to their interference 
with serotonin metabolism. Reduced serotonin availability is a result of one or more of the following: (i) the  
serotonin precursor, tryptophan, is preferentially used for leukocyte activation and synthesis of acute phase 
proteins, instead of for 5-HT synthesis; (ii) indoleamine 2,3 dioxygenase (IDO), an important enzyme in 
tryptophan catabolism, is induced by cytokines such as IFN-γ and IL-6; and (iii) low levels of serum albumin, 
which is essential for tryptophan transport to the blood-brain barrier (Godbout et al., 2005; Maes et al., 1997). 
In conjunction with reduced availability of 5-HT, upregulation of post-synaptic cleft serotonin receptors has 
also been observed in the setting of chronic inflammation (Maes et al., 2011).  
In addition to their effects on neurotransmitters, cytokines may also influence depression development 
through their stimulatory actions on the hypothalamic-pituitary-adrenal axis and downregulation of 
glucocorticoid receptors, resulting in hypercortisolaemia (Maes et al., 1997). 
In this context, one can appreciate the beneficial potential of a supplement a combination of selective 
serotonin-reuptake inhibition, monoamine releasing, anti-oxidant and mild anti-inflammatory properties. 
Sceletium tortuosum is already known to be an effective mood-elevating natural product (Harvey et al., 2011; 
Loria et al., 2014; Smith, 2011), but this current study has revealed a second positive effect of Sceletium 
supplementation – namely that it may directly and beneficially target immune cells in the peripheral 
compartment.  These findings indicate that Sceletium may act as a double-edged sword in attenuation of 
cytokine-induced depression, as well as in psychologically-induced systemic low-grade inflammation. 
Importantly, the current study also provides evidence that the beneficial physiological effects of this plant 
medicine extends beyond its psychoactive effects.   
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The current study design did not allow for the elucidation of specific plant constituents responsible for these 
effects. This warrants further investigation in purpose-designed experiments and in vivo supplementation 
studies. In our opinion, in addition to the different alkaloids generally accepted to be the active constituents, 
anti-oxidant profiling should also be performed, to further elucidate physiological mechanisms of action of 
this promising plant medicine.  
Conclusion  
In conclusion, data presented here suggests that a high-mesembrine Sceletium extract, Trimesemine™, 
beneficially modulates the basal inflammatory cytokine profile without hindering an acute response to 
pathogenic challenge. Furthermore, data suggests that the extract may affect anti-oxidant activity conferring 
significant cytoprotection from endotoxin-associated oxidative stress damage. Given the recent reports 
illustrating increased LPS levels not only in pathogenic infection, but also in chronic diseases such as 
Alzheimer’s disease (Zhao et al., 2017), arthritis (Azzouz and Silverman, 2017) and depression (Zhou et al., 
2017), data suggests a potential broader role for Trimesemine™ in the sphere of preventative 
supplementation.  
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Appendix B – Formulation method for Milliplex kits with diluted beads 
B1 Preparation of reagents for immunoassay: 
1. Preparation of antibody-immobilized beads: 
a) Sonicate each antibody-bead vial for 30 seconds and vortex for one minute 
b) Add 45μl from each antibody-bead vial to the Mixing Bottle and bring final volume to 2800μl with 
Bead Diluent. Vortex the mixture well (Note: this step must be repeated per plate) 
2. Preparation of Detection antibodies: 
a) Add 1600μl of detection antibodies (stock) to 1200μl of Assay Buffer, to achieve a total volume of 
2800μl (Note: this step must be repeated per plate) 
3. Preparation of Quality Controls: 
a) Reconstitute Quality Control 1 and Quality Control 2 with 250μl deionized/distilled water (Note: this 
step does not need to be repeated per plate) 
b) Invert the vials several times to mix, and vortex 
c) Allow vials to sit for 5-10 minutes, then transfer to appropriately-labelled polypropylene microfuge 
vials 
4. Preparation of Wash Buffer: 
a) Bring the 10X Wash Buffer to room temperature and mix to bring all the salts into solution 
b) Dilute 30ml of 10X Wash Buffer with 270ml deionized/distilled water 
5. Preparation of Human Cytokine Standard 
a) Reconstitute the Human Cytokine Standard with 250μl deionized water to give a 10000pg/ml 
concentration of standard for all analytes 
b) Invert the vial several times to mix, and vortex for 10 seconds 
c) Allow vial to sit for 10 minutes, then transfer to appropriately-labelled polypropylene microfuge vial 
6. Preparation of Working standards: 
a) Label five polypropylene microfuge vials: 2000pg/ml, 400pg/ml, 80pg/ml, 16pg/ml and 3.2pg/ml 
b) Add 200μl Assay Buffer to each tube 
c) Prepare serial dilutions according to the following table, vortexing in between each transfer: 
 Standard concentration (pg/ml) Volume of deionised water (µl) Volume of standard 
1 10000 250 - 
2 2000 200 50µl of standard 1 
3 400 200 50µl of standard 2 
4 80 200 50µl of standard 3 
5 16 200 50µl of standard 4 
6 3.2 200 50µl of standard 5 
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B2 Immunoassay procedure (per plate): 
1. Allow all reagents to warm to room temperature (20-25°C) before use in the assay 
2. Add 200μl Wash Buffer into each well of the plate 
3. Seal and mix on plate shaker for 10 minutes at room temperature 
4. Decant wash buffer and remove residual amount from all wells by inverting the plate and tapping it smartly 
several times, onto absorbent towels 
5. Add 25μl of each Standard or Quality Control into the appropriate wells, and Assay Buffer to the 0pg/ml 
standard (background) wells 
6. Add 25μl of Assay Buffer to the sample wells 
7. Add 25μl appropriate control culture medium or serum matrix to the background, standards and quality 
control wells 
8. Add 25μl of cell culture supernatant to the appropriate wells (when NAP2 is measured in plasma, samples 
should be diluted 1:100 in Assay Buffer. Accordingly, serum matrix diluted 1:100 should also be used for 
the standards and quality control wells) 
9. Vortex Mixing Bottle and add 25μl of prepared beads to each well 
10. Seal plate, wrap plate in foil and incubate with agitation on plate shaker for two hours at room 
temperature 
11. Wash plate two times using Bioplex Pro Wash station  
12. Add 25μl of the prepared Detection Antibodies into each well 
13. Seal, cover with foil and incubate with agitation on plate shaker for one hour at room temperature 
14. Add 25μl Streptavidinn-Phycoerythrin to each well 
15. Seal, cover with foil and incubate with agitation on plate shaker for 30 minutes at room temperature 
16. Wash plate two times using Bioplex Pro Wash station  
17. Add 75μl Sheath Fluid to all wells 
18. Re-suspend beads on plate shaker for five minutes 
19. Run plate on the Bio-Plex 200 or MAGPIX instrument 
B3 Equipment settings: 
 Bio-Plex 200 (with Bio-Plex Manager v6.1 software) or Bio-plex MAGPIX (with Bio-Plex MP software) 
 Beads: 50, per region 
 Sample size: 50μl 
 Gate settings: Default 
 photomultiplier tube (PMT) settings: Default (Low RP1) 
 Time out: 60 seconds 
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Appendix C – Information Leaflet and Consent Form 
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Appendix D – Health and Lifestyle Questionnaire 
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Appendix E – State-Trait Anxiety Index Questionnaire 
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Appendix F – Platelet isolation optimisation for platelet assay 
To optimise platelet isolation for suitable yield as well as low activation, four platelet isolation methods 
(derived from available literature) were tested. All methods were tested on blood samples from the same 
individual and were drawn the same day. 
Platelets were stained with mouse anti-human CD41a antibodies, as this marker was initially used as a platelet 
activation marker in coagulation studies. In this context, decreased binding of CD41a antibodies to activated 
platelets has been previously demonstrated (Gobbi et al., 2003). In line with this, CD41a was employed as 
platelet gating marker in the current study. In addition, it provided information on activation status of 
platelets.  
F1 Method 1 
1. Draw blood via antecubital venous puncture (sodium citrate anti-coagulated) 
2. Centrifuge whole blood (200xg, 5 minutes, room temperature, no brake) 
3. Remove plasma (yields ±1ml per 4.5ml blood collection tube) and transfer to new sterile 15ml tube 
4. Add PBS at 1:1 ratio 
5. Perform automated analysis (Celldyne 3700CS, Abbott Diagnostics) 
 Platelet yield: 2.1x109 platelets/L 
F2 Method 2 
1. Draw blood via antecubital venous puncture (sodium citrate anti-coagulated) 
2. Centrifuge whole blood (200xg, 20 minutes, 20°C, no brake) 
3. Remove plasma (yields ±1.5ml per 4.5ml blood collection tube) and transfer to new sterile 15ml tube 
4. Perform automated analysis (Celldyne 3700CS, Abbott Diagnostics) 
 Platelet yield: 145x109 platelets/L 
F3 Method 3 
1. Draw blood via antecubital venous puncture (sodium citrate anti-coagulated) 
2. Centrifuge whole blood (200xg, 20 minutes, room temperature, no brake) 
3. Remove plasma (yields ±2ml per 4.5ml blood collection tube) and transfer to new sterile 15ml tube 
4. Add PBS at 1:1 ratio 
5. Centrifuge (800xg, 20 minutes, room temperature) 
6. Resuspend platelet pellet in PBS 
7. Perform automated analysis (Celldyne 3700CS, Abbott Diagnostics) 
 Platelet yield: 63.9x109 platelets/L 
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F4 Method 4 
1. Draw blood via antecubital venous puncture (sodium citrate anti-coagulated) 
2. Centrifuge whole blood (400xg, 15 minutes, room temperature, no brake) 
3. Remove plasma (yields ±2ml per 4.5ml blood collection tube) and transfer to new sterile 15ml tube 
4. Centrifuge (400xg, 15 minutes, room temperature, no brake) 
5. Aspirate PPP (upper ±1/3 of plasma) 
6. Resuspend platelet pellet in PRP (lower ±2/3 of plasma) 
7. Perform automated analysis (Celldyne 3700CS, Abbott Diagnostics) 
 Platelet yield: 46.7x109 platelets/L 
 
Following automated analysis for platelet count (all methods): 
1. Add 500µl 1X BD FACS-lyse solution to plasma, incubate for 10 minutes at room temperature 
2. Add 1ml PBS into the sample tube 
3. Centrifuge (800xg, 20 minutes, room temperature) 
4. Remove supernatant and resuspend platelet pellet in 500µl 0.1% saponin, incubate for 10 minutes at 
room temperature 
5. Add 2ml PBS into the sample tube 
6. Centrifuge (800xg, 20 minutes, 4°C) 
7. Remove supernatant and resuspend platelet pellet in 100µl PBS with 3% FBS 
8. Add conjugated antibodies for CD41a 
9. Incubate platelets in the dark for 30 minutes at 4°C 
10. Perform final wash step with PBS and centrifuge (400xg, 5 minutes, 4°C) 
11. Resuspended in 1% paraformaldehyde and assess by flow cytometric analysis 
Flow cytometry scatter plots illustrating CD41a+ platelets can be seen in Figure 7.1. Gating parameters were 
previously determined through fluorescence minus one (FMO) controls and single stain sample analysis 
(Appendix G).  





Figure 7.1 Flow cytometry scatterplots showing platelet gating and CD41a+ platelets 
The results of flow cytometric analysis of activation of the samples acquired through each method, are 
quantified in Table 7.1. 
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Table 7.1: Flow cytometry results indicating degree of platelet activation based on CD41a expression 
 
It was concluded that Method 4 was the optimal platelet isolation method to employ, in terms of favourable 
platelet yield with low platelet activation. This was important for the subsequent platelet assay, where platelet 
activation in response to treatment exposure would be measured. 
  
 CD41a (mean fluorescent intensity) CD41a+ platelets (% total platelet count) 
Method 1 2579 15.9 
Method 2 3833 14 
Method 3 2449 26.9 
Method 4 3859 84.5 
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Appendix G – Flow cytometric analysis 
G1 Description of instrument 
The BD FACSAria IIu flow cytometer (BD Biosciences, USA) was employed for the analysis of samples, housed 
in the Central Analytic Facilities Fluorescent Imaging Unit, Stellenbosch University.  The instrument is a high-
speed benchtop cell sorter, able to acquire up to 70,000 events per second. The flow cytometer is fitted with 
blue (488-nm), red (633-nm) and violet (405-nm) solid state lasers for multicolour analysis of ≤9 fluorescent 
markers and two physical parameters, forward scatter (FSC) and side scatter (SSC). It is also equipped with two 
types of signal detectors; PMTs and a photodiode detector. PMTs detect signals generated by SSC and all 
fluorescence channels, whereas the photodiode signal generated by FSC. 
The BD FACSAria IIu possesses an octagon and two trigon detector arrays. The octagon detector array contains 
6 PMTs that detect SSC and up to five fluorescence signals excited by the blue laser. The trigon arrays detect 
fluorescence signals excited by the red and violet lasers. Each trigon contains two PMTs that detect up to two 
fluorescence channels. The PMTs within each array convert light into electrical pulses that can be processed 
by the electronics system and converted into data. Acquisition and data analysis, as well as most BD FACSAria 
II cytometer functions, are performed on BD FACSDiva v8.1 software. 
Table 7.2 displays the filters (longpass and bandpass), detectors and voltage settings employed in the astrocyte 
propidium iodide viability assay.  
Table 7.2: Instrument parameters for astrocyte propidium iodide viability assay by flow cytometry 
Laser LP filter BP filter Detector Parameter Voltage Amplification 
488nm 
n/a 488/10 SSC (PD) SSC-A 280 Linear 
502LP 610/20 488-C BD Horizon™ PE-CF594 410 Log 
 
The following table displays the filters (longpass and bandpass), detectors and voltage settings employed in 
the platelet assay: 
Table 7.3: Instrument parameters for platelet assay by flow cytometry 
Laser LP filter BP filter Detector Parameter Voltage Amplification 
488nm 
n/a 488/10 SSC (PD) SSC-A 250 Linear 
502 530/30 488-F Alexa Fluor™ 488 443 Log 
595 610/20 488-C BD Horizon™ PE-CF594 540 Log 
735 780/60 488-A BD Horizon™ PE-Cyanine7 580 Log 
633 nm 735 660/20 633-B Alexa Fluor™ 647 420 Log 
405nm 502 450/40 405-B Alexa Fluor™ 405 449 Log 
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G2 Antibody information and titration protocol for platelet assay 
Characteristics of all antibodies used in the platelet assay are summarised in Table 7.4. 
Table 7.4: Platelet assay antibody characteristics  
Marker  Host Species reactivity Clonality Isotype Fluorochrome 
Serotonin Rat  Human Monoclonal IgG2 None  
Anti-rat IgG Donkey Rat Polyclonal IgG Alexa Fluor™ 647 
SERT Goat Human, mouse Polyclonal IgG1 None 
Anti-goat IgG Donkey Goat Polyclonal IgG Alexa Fluor™ 488 
VMAT-2 Mouse Human Monoclonal IgG1 Alexa Fluor™ 405 
CD41a Mouse Human Monoclonal  IgG1 
BD Horizon™ PE-
Cyanine7 




To optimise antibody concentrations for platelet flow cytometric analysis, antibody titrations were performed 
on isolated platelets, activated with calcium ionophore A23187. This ensured that all markers of interest would 
be expressed. Antibodies were diluted according to the following table: 














Serotonin 0.5 100 1:10-1:500 1µl 0.5µl* 0.25µl 
Anti-rat IgG 2 500 0.5µl 0.5µl* - - 
SERT 1 200 5µl 2.5µl* 2µl 1.5µl 
Anti-goat IgG 2 500 0.5µl 0.5µl* - - 
VMAT-2 0.2 100 0.25-1µg per 106 cells 1.25µl* 1µl 0.75µl 
CD41a 0.0025 500 5µl 5µl 2.5µl* 1.25µl 
CD63 0.0025 500 5µl 5µl* 2.5µl 1.25µl 
* Optimal concentrations determined by flow cytometry 
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G3 Instrument setup and controls 
For compensation controls, single-stained cell controls were prepared for each antibody in the staining panel. 
The cell controls were then acquired on the BD FACSAria IIu and analysed for the percentage of spill over for 
each tested antibody. The resulting compensation matrix was then applied to the samples and employed for 
the analysis of the samples. Table 7.6 illustrates the compensation matrix, expressed as a percentage. 












Alexa Fluor™ 488 100 16.07 0.81 0.03 0.75 
BD Horizon™ PE-
CF594 
0.04 100 12.32 0.19 0.00 
PE BD Horizon™ PE-
Cyanine7 
0.02 0.55 100 0.01 0.00 
Alexa Fluor™ 647 0.00 0.00 0.63 100 0.00 
Alexa Fluor™ 405 0.00 0.00 0.00 0.00 100 
 
To ensure that the gating strategy employed was able to accurately differentiate true positive and negative 
populations, FMO controls were performed for the regions of interest.  
For the experiment, application settings were used to determine optimal voltage settings for each parameter 
and as an internal experimental control 8-peak rainbow beads were used to ensure that mean fluorescent 
intensity (MFI) changes remained constant. 
G4 Sample acquisition and analysis of platelet assay 
Before acquisition, the sample tubes and beads were vortexed for 5 seconds to ensure that the cells and beads 
were well suspended. BD FACSDiva™ software was used for data acquisition and analysis. A minimum of 40 
0000 gated events were collected for each sample tube. 
To identify platelets, a FSC-H versus CD41a dot plot was employed and all CD41a+ cells were gated. Within the 
CD41+ population, doublets were excluded by using a double discrimination gate (FSC-H vs FSC-A), which was 
performed to exclude clumped cells. All other parameters were determined from the resulting singlet cells 
(Figure 7.2). For the study, we reported both changes in frequency as well as MFI.  
For statistical analysis of the flow cytometric data, data was exported to excel format and incorporated into 
statistical software. 
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G5 Representative images of gating for all parameters of interest 
 
 
Figure 7.2: Gating strategies for platelet parameters in control and calcium ionophore A23187-activated 
platelets 
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